Tekla Life Sciences Investors (HQL) N-PX Annual report of proxy voting record

UNITED STATES	OMB APPROVAL
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549	OMB Number:  3235-0582
	Expires:  July 31, 2024
	Estimated average burden hours per response........4

FORM N-PX

ANNUAL REPORT OF PROXY VOTING RECORD OF REGISTERED
MANAGEMENT INVESTMENT COMPANY

Investment Company Act file number  811- 06565

Tekla Life Sciences Investors

(Exact name of registrant as specified in charter)

100 Federal Street, 19th Floor, Boston, MA	02110
(Address of principal executive offices)	(Zip code)

Laura Woodward
Tekla Life Sciences Investors
100 Federal Street, 19^th Floor, Boston MA 02110

(Name and address of agent for service)

Registrant’s telephone number, including area code:  617-772-8500

Date of fiscal year end:  September 30

Date of reporting period:  7/1/22-6/30/23

Form N-PX is to be used by a registered management investment company, other than a small business investment company registered on Form N-5 (ss.ss. 239.24 and 274.5 of this chapter), to file reports with the Commission, no later than August 31 of each year, containing the registrant’s proxy voting record for the most recent twelve-month period ended June 30, pursuant to section 30 of the Investment Company Act of 1940 and rule 30b1-4 thereunder (17 CFR 270.30b1-4). The Commission may use the information provided on Form N-PX in its regulatory, disclosure review, inspection, and policymaking roles.

A registrant is required to disclose the information specified by Form N-PX, and the Commission will make this information public. A registrant is not required to respond to the collection of information contained in Form N-PX unless the Form displays a currently valid Office of Management and Budget (“OMB”) control number. Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549-0609. The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. ss. 3507.

Item 1. Proxy Voting Record.

Vote Summary

89BIO, INC.

Security	282559103	Meeting Type	Annual
Ticker Symbol	ETNB	Meeting Date	05-Jun-2023
Record Date	06-Apr-2023

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Rohan Palekar		For	For
	2	E. M. Atkinson III, PhD		For	For
	3	Gregory Grunberg, M.D.		For	For
2.	Approval of an amendment to our Certificate of Incorporation to increase the number of authorized shares of our common stock.		Management	For	For
3.	Ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2023.		Management	For	For

ADAPTIVE BIOTECHNOLOGIES CORPORATION

Security	00650F109	Meeting Type	Annual
Ticker Symbol	ADPT	Meeting Date	09-Jun-2023
Record Date	12-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	To elect Class I director nominee to serve on the board of directors of Adaptive Biotechnologies Corporation for a three-year term expiring at the 2026 annual meeting of shareholders: Katey Owen, PhD	Management	For	For
1.2	To elect Class I director nominee to serve on the board of directors of Adaptive Biotechnologies Corporation for a three-year term expiring at the 2026 annual meeting of shareholders: Robert Hershberg, PhD, MD	Management	For	For
2.	To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in the proxy statement.	Management	For	For
3.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2023.	Management	For	For

ADICET BIO, INC.

Security	007002108	Meeting Type	Annual
Ticker Symbol	ACET	Meeting Date	01-Jun-2023
Record Date	04-Apr-2023

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Carl L. Gordon,PhD, CFA		For	For
	2	Steve Dubin, J.D.		For	For
	3	Jeffrey Chodakewitz MD		For	For
2.	To amend and restate the Company's Amended and Restated 2018 Stock Option and Incentive Plan.		Management	For	For
3.	To ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.		Management	For	For

AFFIMED N.V

Security	N01045108	Meeting Type	Annual
Ticker Symbol	AFMD	Meeting Date	21-Jun-2023
Record Date	24-May-2023

Item	Proposal	Proposed by	Vote	For/Against Management
3.	Adoption of the Statutory Annual Accounts for the financial year 2022	Management	For	For
4.	Advisory vote (non-binding) on Executive Compensation	Management	For	For
5.	Discharge of the managing directors for their management during the financial year 2022	Management	For	For
6.	Discharge of the supervisory directors for their supervision during the financial year 2022	Management	For	For
7.	Amendment of the Remuneration Policy for the Supervisory Board	Management	For	For
8a.	Reappointment of Dr. Adi Hoess as a managing director	Management	For	For
8b.	Reappointment of Dr. Wolfgang Fischer as a managing director	Management	For	For
8c.	Reappointment of Mr. Angus Smith as a managing director	Management	For	For
8d.	Reappointment of Dr. Arndt Schottelius as a managing director	Management	For	For
8e.	Reappointment of Dr. Andreas Harstrick as a managing director	Management	For	For
9a.	Reappointment of Dr. Thomas Hecht as a supervisory director	Management	For	For
9b.	Reappointment of Mr. Harry Welten as a supervisory director	Management	For	For
9c.	Reappointment of Dr. Annalisa M. Jenkins as a supervisory director	Management	For	For
9d.	Appointment of Dr. Constanze Ulmer-Eilfort as a supervisory director	Management	For	For
10.	Reverse stock split and amendment of the articles of association	Management	For	For
11.	Authorization to acquire shares	Management	For	For
12.	Appointment of the auditor for the financial year 2023	Management	For	For

ALKERMES PLC

Security	G01767105	Meeting Type	Contested-Annual
Ticker Symbol	ALKS	Meeting Date	29-Jun-2023
Record Date	17-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	BOARD NOMINEE: Emily Peterson Alva	Management	For	For
1B.	BOARD NOMINEE: Shane M. Cooke	Management	For	For
1C.	BOARD NOMINEE: Richard B. Gaynor, M.D.	Management	For	For
1D.	BOARD NOMINEE: Cato T. Laurencin, M.D., Ph.D.	Management	For	For
1E.	BOARD NOMINEE: Brian P. McKeon	Management	For	For
1F.	BOARD NOMINEE: Richard F. Pops	Management	For	For
1G.	BOARD NOMINEE: Christopher I. Wright, M.D., Ph.D.	Management	For	For
1H.	SARISSA NOMINEE: Patrice Bonfiglio	Management	Withheld	For
1I.	SARISSA NOMINEE: Alexander Denner, Ph.D.	Management	Withheld	For
1J.	SARISSA NOMINEE: Sarah J. Schlesinger, M.D.	Management	Withheld	For
2.	To approve, in a non-binding, advisory vote, the compensation of the Company's named executive officers.	Management	For	For
3.	To ratify, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the independent auditor and accounting firm of the Company and to authorize, in a binding vote, the Audit and Risk Committee of the Board to set the independent auditor and accounting firm's remuneration.	Management	For	For
4.	To approve the Alkermes plc 2018 Stock Option and Incentive Plan, as amended.	Management	For	For
5.	To renew Board authority to allot and issue shares under Irish law.	Management	For	For
6.	To renew Board authority to disapply the statutory pre- emption rights that would otherwise apply under Irish law.	Management	For	For

ALNYLAM PHARMACEUTICALS, INC.

Security	02043Q107	Meeting Type	Annual
Ticker Symbol	ALNY	Meeting Date	18-May-2023
Record Date	24-Mar-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class I Director: Michael W. Bonney	Management	For	For
1b.	Election of Class I Director: Yvonne L. Greenstreet, MBChB, MBA	Management	For	For
1c.	Election of Class I Director: Phillip A. Sharp, Ph.D.	Management	For	For
1d.	Election of Class I Director: Elliott Sigal, M.D., Ph.D.	Management	For	For
2.	To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.	Management	For	For
3.	To recommend, in a non-binding advisory vote, the frequency of advisory stockholder votes on executive compensation.	Management	1 Year	For
4.	To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam's independent auditors for the fiscal year ending December 31, 2023.	Management	For	For

ALTIMMUNE INC.

Security	02155H200	Meeting Type	Annual
Ticker Symbol	ALT	Meeting Date	29-Sep-2022
Record Date	12-Aug-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Mitchel Sayare, Ph.D.		For	For
	2	Vipin K. Garg, Ph.D.		For	For
	3	David J. Drutz, M.D.		For	For
	4	John M. Gill		For	For
	5	Philip L. Hodges		For	For
	6	Diane Jorkasky, M.D.		For	For
	7	Wayne Pisano		For	For
	8	Klaus O.Schafer,M.D.MPH		For	For
2.	Vote to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2022.		Management	For	For
3.	Hold an advisory vote on the compensation of the Company's named executive officers as disclosed in the attached Proxy Statement.		Management	For	For
4.	Approve the authorization to adjourn the Annual Meeting, if necessary or appropriate, to solicit additional proxies in favor of the foregoing proposals if there are not sufficient votes to approve the proposals.		Management	For	For

ALX ONCOLOGY HOLDINGS INC

Security	00166B105	Meeting Type	Annual
Ticker Symbol	ALXO	Meeting Date	16-Jun-2023
Record Date	19-Apr-2023

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Scott Garland		For	For
	2	Rekha Hemrajani		For	For
	3	Jaume Pons, Ph.D.		For	For
2.	Advisory vote to approve named executive officer compensation.		Management	For	For
3.	Ratification of the appointment of KPMG LLP as the independent registered public accounting firm for our fiscal year ending December 31, 2023.		Management	For	For

AMGEN INC.

Security	031162100	Meeting Type	Annual
Ticker Symbol	AMGN	Meeting Date	19-May-2023
Record Date	20-Mar-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director for a term of office expiring at the 2024 annual meeting: Dr. Wanda M. Austin	Management	For	For
1b.	Election of Director for a term of office expiring at the 2024 annual meeting: Mr. Robert A. Bradway	Management	For	For
1c.	Election of Director for a term of office expiring at the 2024 annual meeting: Dr. Michael V. Drake	Management	For	For
1d.	Election of Director for a term of office expiring at the 2024 annual meeting: Dr. Brian J. Druker	Management	For	For
1e.	Election of Director for a term of office expiring at the 2024 annual meeting: Mr. Robert A. Eckert	Management	For	For
1f.	Election of Director for a term of office expiring at the 2024 annual meeting: Mr. Greg C. Garland	Management	For	For
1g.	Election of Director for a term of office expiring at the 2024 annual meeting: Mr. Charles M. Holley, Jr.	Management	For	For
1h.	Election of Director for a term of office expiring at the 2024 annual meeting: Dr. S. Omar Ishrak	Management	For	For
1i.	Election of Director for a term of office expiring at the 2024 annual meeting: Dr. Tyler Jacks	Management	For	For
1j.	Election of Director for a term of office expiring at the 2024 annual meeting: Ms. Ellen J. Kullman	Management	For	For
1k.	Election of Director for a term of office expiring at the 2024 annual meeting: Ms. Amy E. Miles	Management	For	For
1l.	Election of Director for a term of office expiring at the 2024 annual meeting: Dr. Ronald D. Sugar	Management	For	For
1m.	Election of Director for a term of office expiring at the 2024 annual meeting: Dr. R. Sanders Williams	Management	For	For
2.	Advisory vote on the frequency of future stockholder advisory votes to approve executive compensation.	Management	1 Year	For
3.	Advisory vote to approve our executive compensation.	Management	For	For
4.	To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2023.	Management	For	For

AMOLYT PHARMA

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	21-Jun-2023
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Approval of the company’s 2022 financials and earnings, discharge of the President for the performance of his duties during the past fiscal year	Management	For	For
2.	Approval of amendment No. 1 dated November 13, 2022 and the amendment No. 2 dated January 6, 2023 to the service agreement entered into on July 25, 2019 between the Company and Tab Consulting, of which Mr. Thierry Abribat is chairman, the terms of which are described in the special report of the Statutory Auditor	Management	For	For
3.	Approval of amendment No.2 dated April 7, 2022 and the amendment No. 3 dated March 8, 2023 to the consulting agreement entered into on May 6, 2020 between the Company and Stone Atlanta Estates LLC (formerly Stone Sunny Isles, Inc.), of which Mr. Pierre Legault is president, the terms of which are described in the special report of the Statutory Auditor	Management	For	For
4.	Approval of amendment No.1 dated January 6, 2023 to the indemnification agreement entered into on June 3, 2020 between the Company and Mr. Pierre Legault, the terms of which are described in the special report of the Statutory Auditor.	Management	For	For
5.	Reappointment of Pierre Legault as a member of the Board of Directors	Management	For	For
6.	Approval of the 2023-1 stock option plan adopted by the President on March 1, 2023	Management	For	For

AMPHIVENA THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	26-Sep-2022
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	General Assignment	Management	For	For
2.	Assignment Amendment	Management	For	For

APELLIS PHARMACEUTICALS INC.

Security	03753U106	Meeting Type	Annual
Ticker Symbol	APLS	Meeting Date	01-Jun-2023
Record Date	03-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class III Director to hold office until the 2026 annual meeting: Gerald Chan	Management	For	For
1.2	Election of Class III Director to hold office until the 2026 annual meeting: Cedric Francois	Management	For	For
2.	To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.	Management	For	For
3.	To approve an advisory vote on executive compensation.	Management	For	For

ARCA BIOPHARMA, INC.

Security	00211Y506	Meeting Type	Annual
Ticker Symbol	ABIO	Meeting Date	15-Dec-2022
Record Date	25-Oct-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: Dr. Linda Grais	Management	For	For
1.2	Election of Director: Dr. Anders Hove	Management	For	For
1.3	Election of Director: Mr. James Flynn	Management	For	For
2.	To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022.	Management	For	For
3.	To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in this proxy statement.	Management	For	For

ARCUS BIOSCIENCES, INC.

Security	03969F109	Meeting Type	Annual
Ticker Symbol	RCUS	Meeting Date	15-Jun-2023
Record Date	18-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: David Lacey, M.D.	Management	For	For
1b.	Election of Director: Juan Carlos Jaen, Ph.D.	Management	For	For
1c.	Election of Director: Merdad Parsey, M.D., Ph.D.	Management	For	For
1d.	Election of Director: Nicole Lambert	Management	For	For
2.	To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of Arcus Biosciences for its fiscal year ending December 31, 2023.	Management	For	For
3.	To approve, on an advisory basis, the compensation of Arcus Biosciences' named executive officers, as disclosed in the Proxy Statement.	Management	For	For

ARCUTIS BIOTHERAPEUTICS, INC.

Security	03969K108	Meeting Type	Annual
Ticker Symbol	ARQT	Meeting Date	31-May-2023
Record Date	03-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class III Director to hold office until the 2026 Annual Meeting: Patrick J. Heron	Management	For	For
1b.	Election of Class III Director to hold office until the 2026 Annual Meeting: Neha Krishnamohan	Management	For	For
1c.	Election of Class III Director to hold office until the 2026 Annual Meeting: Todd Franklin Watanabe	Management	For	For
2.	To ratify the selection, by the Audit Committee of the Company's Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023.	Management	For	For
3.	To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.	Management	For	For

ARDELYX, INC

Security	039697107	Meeting Type	Annual
Ticker Symbol	ARDX	Meeting Date	15-Jun-2023
Record Date	18-Apr-2023

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Robert Bazemore		For	For
	2	Muna Bhanji, R.Ph		For	For
	3	Richard Rodgers		For	For
2.	To approve an amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 to 500,000,000 shares.		Management	Against	Against
3.	To approve, on a non-binding, advisory basis, the compensation of our named executive officers as disclosed in the proxy statement accompanying this notice pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on- Pay").		Management	For	For
4.	To ratify the selection, by the Audit and Compliance Committee of our Board of Directors, of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023.		Management	For	For

ARGENX SE

Security	04016X101	Meeting Type	Special
Ticker Symbol	ARGX	Meeting Date	08-Sep-2022
Record Date	02-Aug-2022

Item	Proposal	Proposed by	Vote	For/Against Management
2.	Appointment of Camilla Sylvest as non-executive director to the board of directors of the Company	Management	For

ARGENX SE

Security	04016X101	Meeting Type	Special
Ticker Symbol	ARGX	Meeting Date	12-Dec-2022
Record Date	08-Nov-2022

Item	Proposal	Proposed by	Vote	For/Against Management
2.	Appointment of Ana Cespedes as non-executive director to the board of directors of the Company	Management	Abstain

ARGENX SE

Security	04016X101	Meeting Type	Annual
Ticker Symbol	ARGX	Meeting Date	02-May-2023
Record Date	04-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
3.	Advisory vote to approve the 2022 remuneration report.	Management	For
4b.	Adoption of the 2022 annual accounts.	Management	For
4d.	Allocation of losses of the Company in the financial year 2021 to the retained earnings of the Company.	Management	For
4e.	Proposal to release the members of the board of directors from liability for their respective duties carried out in the financial year 2022.	Management	For
5.	Proposal to re-appoint Don deBethizy as non-executive director for a term of two years.	Management	For
6.	Authorization of the board of directors to issue shares and grant rights to subscribe for shares in the share capital of the Company up to a maximum of 10% of the outstanding capital at the date of the general meeting, for a period of 18 months from the annual general meeting and to limit or exclude statutory pre-emptive rights, if any.	Management	For
7.	Appointment of Deloitte Accountants B.V. as statutory auditor for the 2023 financial year.	Management	For

ARISTEA THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	7-Jul-2022
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Appoint Independent director	Management	For	For

ARISTEA THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	7-Jul-2022
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Appoint Series A director	Management	For	For

ARKUDA THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	19-Dec-2022
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Second Tranche Closing under Series B Preferred Stock Purchase Agreement	Management	For	For

ARKUDA THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	13-Apr-2023
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Amendment No. 1 to amended and restated voting agreement and stockholder consent	Management	For	For

ARROWHEAD PHARMACEUTICALS, INC.

Security	04280A100	Meeting Type	Annual
Ticker Symbol	ARWR	Meeting Date	16-Mar-2023
Record Date	20-Jan-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Douglass Given	Management	For	For
1b.	Election of Director: Michael S. Perry	Management	For	For
1c.	Election of Director: Christopher Anzalone	Management	For	For
1d.	Election of Director: Marianne De Backer	Management	For	For
1e.	Election of Director: Mauro Ferrari	Management	For	For
1f.	Election of Director: Adeoye Olukotun	Management	For	For
1g.	Election of Director: William Waddill	Management	For	For
1h.	Election of Director: Victoria Vakiener	Management	For	For
2.	Advisory Vote to Approve Executive Compensation.	Management	For	For
3.	Approval of Amendment to Arrowhead Pharmaceuticals, Inc.'s Amended and Restated Certificate Of Incorporation To Increase The Number Of Authorized Shares Of Common Stock.	Management	For	For
4.	To ratify the selection of Rose, Snyder & Jacobs LLP as independent auditors of the Company for the fiscal year ending September 30, 2023.	Management	For	For

ASCENDIS PHARMA A/S

Security	04351P101	Meeting Type	Special
Ticker Symbol	ASND	Meeting Date	09-Sep-2022
Record Date	02-Aug-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.	The Board of Directors proposes that attorney-at-law Lars Lüthjohan is elected as chairman of the general meeting.	Management	For	For
2a.	Election of Class I, Director for a term expiring at the annual general meeting to be held in 2023: William Carl Fairey Jr	Management	For	For
2b.	Election of Class I, Director for a term expiring at the annual general meeting to be held in 2023: Siham Imani	Management	For	For
3.	The board of directors proposes to authorize the chairman of the meeting (with a right of substitution) on behalf of the Company to apply the Danish Business Authority for registration of the resolution passed and in this connection to make any such amendments and supplements to the application and the resolution, including the Company's articles of association and these minutes of the general meeting, that may be required as a condition for registration.	Management	For	For

ASCENDIS PHARMA A/S

Security	04351P101	Meeting Type	Annual
Ticker Symbol	ASND	Meeting Date	30-May-2023
Record Date	21-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.	The Board of Directors proposes that attorney-at-law Lars Lüthjohan is elected as chairman of the general meeting.	Management	For	For
2.	Chairman of the Board, Albert Cha, and Chief Executive Officer, Jan Møller Mikkelsen or Chief Legal Officer, Michael Wolff Jensen will report on the Company's activities for the year ended December 31, 2022.	Management	For	For
3.	The Board of Directors recommends that the audited annual report will be adopted and that a resolution will be passed to discharge the Board of Directors and Management from liability.	Management	For	For
4.	The Board of Directors proposes that the consolidated loss for the year of EUR 583.2 million be carried forward to next year through recognition in accumulated deficit.	Management	For	For
5a.	Re-Election of class I Director for a term expiring at the annual general meeting to be held in 2025: Jan Møller Mikkelsen	Management	For	For
5b.	Re-Election of class I Director for a term expiring at the annual general meeting to be held in 2025: Lisa Morrison	Management	For	For
5c.	Re-Election of class I Director for a term expiring at the annual general meeting to be held in 2025: William Carl Fairey Jr	Management	For	For
5d.	Re-Election of class I Director for a term expiring at the annual general meeting to be held in 2025: Siham Imani	Management	For	For
6.	The Board of Directors proposes that Deloitte Statsautoriseret Revisionspartnerselskab be re-appointed as the Company's auditor.	Management	For	For
7.	Proposal from the Board of Directors The Board of Directors proposes that the following authorization is adopted: The Board of Directors is authorized, in accordance with the Danish Companies Act, Section 198, during the period until 29 May 2028 on one or more occasions to purchase up to nominal DKK 1,000,000 shares or American Depositary Shares representing a corresponding amount of shares in the Company as treasury shares. The minimum price per share shall be DKK 1 and the maximum price per share shall not exceed the market price.	Management	For	For

ASTRAZENECA PLC

Security	046353108	Meeting Type	Annual
Ticker Symbol	AZN	Meeting Date	27-Apr-2023
Record Date	10-Mar-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2022	Management	For	For
2.	To confirm dividends	Management	For	For
3.	To reappoint PricewaterhouseCoopers LLP as Auditor	Management	For	For
4.	To authorise the Directors to agree the remuneration of the Auditor	Management	For	For
5a.	Re-election of Director: Michel Demaré	Management	For	For
5b.	Re-election of Director: Pascal Soriot	Management	For	For
5c.	Re-election of Director: Aradhana Sarin	Management	For	For
5d.	Re-election of Director: Philip Broadley	Management	For	For
5e.	Re-election of Director: Euan Ashley	Management	For	For
5f.	Re-election of Director: Deborah DiSanzo	Management	For	For
5g.	Re-election of Director: Diana Layfield	Management	For	For
5h.	Re-election of Director: Sheri McCoy	Management	For	For
5i.	Re-election of Director: Tony Mok	Management	For	For
5j.	Re-election of Director: Nazneen Rahman	Management	For	For
5k.	Re-election of Director: Andreas Rummelt	Management	For	For
5l.	Re-election of Director: Marcus Wallenberg	Management	For	For
6.	To approve the Annual Report on Remuneration for the year ended 31 December 2022	Management	For	For
7.	To authorise limited political donations	Management	For	For
8.	To authorise the Directors to allot shares	Management	For	For
9.	To authorise the Directors to disapply pre-emption rights (Special Resolution)	Management	For	For
10.	To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments (Special Resolution)	Management	For	For
11.	To authorise the Company to purchase its own shares (Special Resolution)	Management	For	For
12.	To reduce the notice period for general meetings (Special Resolution)	Management	For	For
13.	To adopt new Articles of Association (Special Resolution)	Management	For	For

ASTRAZENECA PLC

Security	046353108	Meeting Type	Annual
Ticker Symbol	AZN	Meeting Date	27-Apr-2023
Record Date	04-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2022	Management	For	For
2.	To confirm dividends	Management	For	For
3.	To reappoint PricewaterhouseCoopers LLP as Auditor	Management	For	For
4.	To authorise the Directors to agree the remuneration of the Auditor	Management	For	For
5a.	Re-election of Director: Michel Demaré	Management	For	For
5b.	Re-election of Director: Pascal Soriot	Management	For	For
5c.	Re-election of Director: Aradhana Sarin	Management	For	For
5d.	Re-election of Director: Philip Broadley	Management	For	For
5e.	Re-election of Director: Euan Ashley	Management	For	For
5f.	Re-election of Director: Deborah DiSanzo	Management	For	For
5g.	Re-election of Director: Diana Layfield	Management	For	For
5h.	Re-election of Director: Sheri McCoy	Management	For	For
5i.	Re-election of Director: Tony Mok	Management	For	For
5j.	Re-election of Director: Nazneen Rahman	Management	For	For
5k.	Re-election of Director: Andreas Rummelt	Management	For	For
5l.	Re-election of Director: Marcus Wallenberg	Management	For	For
6.	To approve the Annual Report on Remuneration for the year ended 31 December 2022	Management	For	For
7.	To authorise limited political donations	Management	For	For
8.	To authorise the Directors to allot shares	Management	For	For
9.	To authorise the Directors to disapply pre-emption rights (Special Resolution)	Management	For	For
10.	To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments (Special Resolution)	Management	For	For
11.	To authorise the Company to purchase its own shares (Special Resolution)	Management	For	For
12.	To reduce the notice period for general meetings (Special Resolution)	Management	For	For
13.	To adopt new Articles of Association (Special Resolution)	Management	For	For

BEAM THERAPEUTICS INC.

Security	07373V105	Meeting Type	Annual
Ticker Symbol	BEAM	Meeting Date	06-Jun-2023
Record Date	10-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class III Director for three-year term ending at the 2026 Annual Meeting: John Evans	Management	For	For
1b.	Election of Class III Director for three-year term ending at the 2026 Annual Meeting: John Maraganore, Ph.D.	Management	For	For
2.	Ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2023.	Management	For	For
3.	Approve, on an advisory basis, the compensation of our named executive officers.	Management	For	For

BEIGENE LTD

Security	07725L102	Meeting Type	Annual
Ticker Symbol	BGNE	Meeting Date	15-Jun-2023
Record Date	17-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.	THAT Dr. Margaret Dugan be and is hereby re-elected to serve as a Class I director of the Company until the 2026 annual general meeting of the shareholders of the Company and until her successor is duly elected and qualified, subject to her earlier resignation or removal.	Management	For	For
2.	THAT John V. Oyler be and is hereby re-elected to serve as a Class I director of the Company until the 2026 annual general meeting of the shareholders of the Company and until his successor is duly elected and qualified, subject to his earlier resignation or removal.	Management	For	For
3.	THAT Dr. Alessandro Riva be and is hereby re-elected to serve as a Class I director until the 2026 annual general meeting of shareholders and until his successor is duly electedand qualified, subject to his earlier resignation or removal.	Management	For	For
4.	THAT the selection of Ernst & Young LLP, Ernst & Young and Ernst & Young Hua Ming LLP as the Company's reporting accounting firms for the fiscal year ending December 31, 2023 be and is hereby approved, ratified and confirmed.	Management	For	For
5.	THAT the Board of Directors is hereby authorized to fix the auditors' remuneration for the fiscal year ending December 31, 2023.	Management	For	For
6.	THAT the granting of a share issue mandate to the Board of ...(due to space limits, see proxy material for full proposal).	Management	For	For
7.	THAT the granting of a share repurchase mandate to the Board of ...(due to space limits, see proxy material for full proposal).	Management	For	For
8.	THAT the Company and its underwriters be and are hereby ...(due to space limits, see proxy material for full proposal).	Management	For	For
9.	THAT the Company and its underwriters be and are hereby ...(due to space limits, see proxy material for full proposal).	Management	For	For
10.	THAT the grant of an option to acquire shares to Amgen to allow ...(due to space limits, see proxy material for full proposal).	Management	For	For
11.	THAT the grant of restricted share units ("RSUs") with a grant date fair value of US$5,500,000 to Mr. John V. Oyler under the Second Amended and Restated 2016 Share Option and Incentive Plan (as amended, the "2016 Plan"), according to the terms and conditions described in the Proxy Statement, be and is hereby approved.	Management	For	For
12.	THAT the grant of RSUs with a grant date fair value of ...(due to space limits, see proxy material for full proposal).	Management	For	For
13.	THAT the grant of RSUs with a grant date fair value of ...(due to space limits, see proxy material for full proposal).	Management	For	For
14.	THAT, on a non-binding, advisory basis, the compensation of the ...(due to space limits, see proxy material for full proposal).	Management	For	For
15.	THAT the Seventh Amended and Restated Memorandum and Articles of Association of the Company, as described in the Proxy Statement, be and is hereby approved.	Management	For	For
16.	THAT the adjournment of the Annual Meeting by the chairman, if ...(due to space limits, see proxy material for full proposal).	Management	For	For

BELLICUM PHARMACEUTICALS, INC.

Security	079481404	Meeting Type	Special
Ticker Symbol	BLCM	Meeting Date	05-Dec-2022
Record Date	11-Oct-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To approve an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended to date, to increase the number of authorized shares of common stock from 80,000,000 to 160,000,000.	Management	For	For
2.	To approve the adjournment of the Special Meeting, to solicit additional proxies if there are not sufficient votes in favor of proposal 1.	Management	For	For

BICYCLE THERAPEUTICS PLC

Security	088786108	Meeting Type	Annual
Ticker Symbol	BCYC	Meeting Date	13-Jun-2023
Record Date	21-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To re elect as a director Janice Bourque, who retires in accordance with the Articles of Association.	Management	For	For
2.	To re elect as a director Veronica Jordan, who retires in accordance with the Articles of Association.	Management	For	For
3.	To re-elect as a director Sir Greg Winter, who retires in accordance with the Articles of Association.	Management	For	For
4.	To approve, on advisory basis, the compensation of our named executive officers.	Management	For	For
5.	To ratify the appointment of PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as our U.S. independent registered public accounting firm for the year ending December 31, 2023.	Management	For	For
6.	To re appoint PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as our U.K statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders.	Management	For	For
7.	To authorize the Audit Committee to determine our U.K statutory auditors' remuneration for the year ending December 31, 2023.	Management	For	For
8.	To receive and adopt our U.K. statutory annual accounts and reports for the year ended December 31, 2022 (the "2022 U.K. Annual Report").	Management	For	For
9.	To approve our U.K. directors' remuneration report for the year ended December 31, 2022 (excluding the directors' remuneration policy).	Management	For	For
10.	To approve the directors' remuneration policy.	Management	For	For

BIOCRYST PHARMACEUTICALS, INC.

Security	09058V103	Meeting Type	Annual
Ticker Symbol	BCRX	Meeting Date	13-Jun-2023
Record Date	17-Apr-2023

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	George B. Abercrombie		For	For
	2	Theresa M. Heggie		For	For
	3	Amy E. McKee, M.D.		For	For
	4	Jon P. Stonehouse		For	For
2.	To ratify the selection of Ernst & Young LLP as the Company's independent registered public accountants for 2023.		Management	For	For
3.	To approve, on an advisory basis, the Company's executive compensation.		Management	For	For
4.	To provide an advisory vote on the frequency of future advisory votes on the Company's executive compensation.		Management	1 Year	For
5.	To approve an amended and restated Stock Incentive Plan, increasing the number of shares available for issuance under the Stock Incentive Plan by 7,000,000 shares.		Management	For	For

BIOGEN INC.

Security	09062X103	Meeting Type	Annual
Ticker Symbol	BIIB	Meeting Date	26-Jun-2023
Record Date	20-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director to serve for a one-year term extending until the 2024 Annual Meeting: Not Applicable	Management	For	For
1b.	Election of Director to serve for a one-year term extending until the 2024 Annual Meeting: Caroline D. Dorsa	Management	For	For
1c.	Election of Director to serve for a one-year term extending until the 2024 Annual Meeting: Maria C. Freire	Management	For	For
1d.	Election of Director to serve for a one-year term extending until the 2024 Annual Meeting: William A. Hawkins	Management	For	For
1e.	Election of Director to serve for a one-year term extending until the 2024 Annual Meeting: Not Applicable	Management	For	For
1f.	Election of Director to serve for a one-year term extending until the 2024 Annual Meeting: Jesus B. Mantas	Management	For	For
1g.	Election of Director to serve for a one-year term extending until the 2024 Annual Meeting: Not Applicable	Management	For	For
1h.	Election of Director to serve for a one-year term extending until the 2024 Annual Meeting: Eric K. Rowinsky	Management	For	For
1i.	Election of Director to serve for a one-year term extending until the 2024 Annual Meeting: Stephen A. Sherwin	Management	For	For
1j.	Election of Director to serve for a one-year term extending until the 2024 Annual Meeting: Christopher A. Viehbacher	Management	For	For
2.	To ratify the selection of PricewaterhouseCoopers LLP as Biogen Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2023.	Management	For	For
3.	Say on Pay - To approve an advisory vote on executive compensation.	Management	For	For
4.	Say When on Pay - To approve an advisory vote on the frequency of the advisory vote on executive compensation.	Management	1 Year	For
5.	To elect Susan Langer as a director	Management

BIOHAVEN LTD

Security	G1110E107	Meeting Type	Annual
Ticker Symbol	BHVN	Meeting Date	02-May-2023
Record Date	06-Mar-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director for a term expiring at the 2026 Annual Meeting of shareholders: Michael T. Heffernan	Management	For	For
1b.	Election of Director for a term expiring at the 2026 Annual Meeting of shareholders: Irina A. Antonijevic, M.D., Ph.D.	Management	For	For
1c.	Election of Director for a term expiring at the 2026 Annual Meeting of shareholders: Robert J. Hugin	Management	For	For
2.	Ratification of appointment of Ernst & Young LLP as independent auditors for fiscal year 2023.	Management	For	For

BIOHAVEN PHARMACEUTICAL HLDG CO LTD

Security	G11196105	Meeting Type	Special
Ticker Symbol	BHVN	Meeting Date	29-Sep-2022
Record Date	29-Aug-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To adopt (i) the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven"), Pfizer Inc. & Bulldog (BVI) Ltd., (ii) the form of Plan of Reverse Triangular Merger & form of Plan of Forward Triangular Merger (together, the "Plan of Merger") & (iii) Separation & Distribution Agreement, dated as of May 9, 2022 ("Distribution Agreement"), by and between Biohaven & Biohaven Research Ltd. ("SpinCo"), in each case, as they may be amended from time to time.	Management	For	For
2.	To approve, by non-binding, advisory vote, certain compensatory arrangements for Biohaven's named executive officers in connection with the acquisition by Pfizer of Biohaven and the distribution to Biohaven's shareholders of all of the issued and outstanding common shares of SpinCo.	Management	For	For
3.	To adjourn the Special Meeting, if necessary, desirable or appropriate, to solicit additional proxies if, at the time of the Special Meeting, there are an insufficient number of votes to adopt the Merger Agreement, the Plan of Merger and the Distribution Agreement.	Management	For	For

BIOMARIN PHARMACEUTICAL INC.

Security	09061G101	Meeting Type	Annual
Ticker Symbol	BMRN	Meeting Date	23-May-2023
Record Date	27-Mar-2023

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Mark J. Alles		For	For
	2	Elizabeth M. Anderson		For	For
	3	Jean-Jacques Bienaimé		For	For
	4	Willard Dere		For	For
	5	Elaine J. Heron		For	For
	6	Maykin Ho		For	For
	7	Robert J. Hombach		For	For
	8	V. Bryan Lawlis		For	For
	9	Richard A. Meier		For	For
	10	David E.I. Pyott		For	For
	11	Dennis J. Slamon		For	For
2.	To ratify the selection of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2023.		Management	For	For
3.	To approve, on an advisory basis, the frequency of the stockholders' approval, on an advisory basis, of the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.		Management	1 Year	For
4.	To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.		Management	For	For
5.	To approve an amendment to the Company's 2017 Equity Incentive Plan, as amended.		Management	For	For

BIONTECH SE

Security	09075V102	Meeting Type	Annual
Ticker Symbol	BNTX	Meeting Date	25-May-2023
Record Date	17-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
2	Resolution on the appropriation of the balance sheet profit for the financial year 2021.	Management	For	For
3	Resolution on the appropriation of the balance sheet profit for the financial year 2022.	Management	For	For
4	Resolution on the approval of the actions of the Management Board.	Management	For	For
5	Resolution on the approval of the actions of the Supervisory Board.	Management	For	For
6	Resolution on the appointment of the auditor of the financial statements and the auditor of the consolidated financial statements for the financial year 2023 as well as the auditor for a possible audit or audit review of interim reports.	Management	For	For
7	Resolution on the approval of the remuneration report.	Management	For	For
8.1	Election to the Supervisory Board: Baroness Nicola Blackwood	Management	For	For
8.2	Election to the Supervisory Board: Ulrich Wandschneider, Ph.D.	Management	For	For
8.3	Election to the Supervisory Board: Mr. Michael Motschmann	Management	For	For
9	Resolution on the Amendment to Sec. 16 para. 5 of the Articles of Association to authorise the Management Board to provide for the holding of a virtual Annual General Meeting.	Management	For	For
10	Resolution on the Amendment to Sec. 16 para. 4 of the Articles of Association on the participation of members of the Supervisory Board in the Annual General Meeting by means of video and audio transmission.	Management	For	For
11a	Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and BioNTech Idar-Oberstein Services GmbH as dependent company.	Management	For	For
11b	Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and NT Security and Services GmbH as dependent company.	Management	For	For
11c	Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and BioNTech BioNTainer Holding GmbH as dependent company.	Management	For	For
11d	Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and BioNTech Individualized mRNA Manufacturing GmbH as dependent company.	Management	For	For

BLACK DIAMOND THERAPEUTICS, INC.

Security	09203E105	Meeting Type	Annual
Ticker Symbol	BDTX	Meeting Date	16-May-2023
Record Date	20-Mar-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class III Director: David M. Epstein	Management	For	For
1b.	Election of Class III Director: Wendy L. Dixon	Management	For	For
1c.	Election of Class III Director: Kapil Dhingra	Management	For	For
2.	To ratify the appointment of PricewaterhouseCoopers LLP as Black Diamond Therapeutics, Inc.'s independent registered accounting firm for the fiscal year ending December 31, 2023.	Management	For	For

BLUEPRINT MEDICINES CORPORATION

Security	09627Y109	Meeting Type	Annual
Ticker Symbol	BPMC	Meeting Date	21-Jun-2023
Record Date	24-Apr-2023

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Alexis Borisy		For	For
	2	Lonnel Coats		For	For
	3	Kathryn Haviland		For	For
2.	Approve a non-binding, advisory vote on the compensation paid to our named executive officers.		Management	For	For
3.	Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.		Management	For	For

BRIDGEBIO PHARMA INC.

Security	10806X102	Meeting Type	Annual
Ticker Symbol	BBIO	Meeting Date	21-Jun-2023
Record Date	24-Apr-2023

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	James C. Momtazee		For	For
	2	Frank McCormick, Ph.D.		For	For
	3	Randal W. Scott, Ph.D.		For	For
	4	Hannah A. Valantine MD		For	For
2.	To cast a non-binding, advisory vote to approve the compensation of the Company's named executive officers.		Management	For	For
3.	To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023.		Management	For	For

CARIBOU BIOSCIENCES, INC.

Security	142038108	Meeting Type	Annual
Ticker Symbol	CRBU	Meeting Date	20-Sep-2022
Record Date	04-Aug-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class 1 Director: Scott Braunstein, M.D.	Management	For	For
1b.	Election of Class 1 Director: Ran Zheng, M.S.	Management	For	For
2.	Ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022	Management	For	For

CARIBOU BIOSCIENCES, INC.

Security	142038108	Meeting Type	Annual
Ticker Symbol	CRBU	Meeting Date	15-Jun-2023
Record Date	17-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class II Director: Andrew Guggenhime, M.B.A.	Management	For	For
1b.	Election of Class II Director: David L. Johnson, M.B.A.	Management	For	For
1c.	Election of Class II Director: Nancy Whiting, Pharm.D.	Management	For	For
2.	Ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023	Management	For	For

CEREVEL THERAPEUTICS HOLDINGS, INC.

Security	15678U128	Meeting Type	Annual
Ticker Symbol	CERE	Meeting Date	07-Jun-2023
Record Date	10-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class III Director for a three-year term expiring at the 2026 Annual Meeting: Marijn Dekkers	Management	For	For
1.2	Election of Class III Director for a three-year term expiring at the 2026 Annual Meeting: Deval Patrick	Management	For	For
1.3	Election of Class III Director for a three-year term expiring at the 2026 Annual Meeting: Norbert Riedel	Management	For	For
1.4	Election of Class III Director for a three-year term expiring at the 2026 Annual Meeting: Gabrielle Sulzberger	Management	For	For
2.	To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in the proxy statement.	Management	For	For
3.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2023.	Management	For	For

CHARLES RIVER LABORATORIES INTL., INC.

Security	159864107	Meeting Type	Annual
Ticker Symbol	CRL	Meeting Date	09-May-2023
Record Date	16-Mar-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: James C. Foster	Management	For	For
1b.	Election of Director: Nancy C. Andrews	Management	For	For
1c.	Election of Director: Robert Bertolini	Management	For	For
1d.	Election of Director: Deborah T. Kochevar	Management	For	For
1e.	Election of Director: George Llado, Sr.	Management	For	For
1f.	Election of Director: Martin W. Mackay	Management	For	For
1g.	Election of Director: George E. Massaro	Management	For	For
1h.	Election of Director: C. Richard Reese	Management	For	For
1i.	Election of Director: Craig B. Thompson	Management	For	For
1j.	Election of Director: Richard F. Wallman	Management	For	For
1k.	Election of Director: Virginia M. Wilson	Management	For	For
2.	Advisory Approval of 2022 Executive Officer Compensation	Management	For	For
3.	Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation	Management	1 Year	For
4.	Ratification of PricewaterhouseCoopers LLC as independent registered public accounting firm for 2023	Management	For	For
5.	Proposal to publish a report on non-human primates imported by Charles River Laboratories International, Inc.	Management	Against	For

CHEMOCENTRYX, INC.

Security	16383L106	Meeting Type	Special
Ticker Symbol	CCXI	Meeting Date	18-Oct-2022
Record Date	13-Sep-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To adopt the Agreement and Plan of Merger, dated as of August 3, 2022 (the "Merger Agreement"), by and among ChemoCentryx, Inc. ("ChemoCentryx"), Amgen Inc. ("Amgen") and Carnation Merger Sub, Inc., a wholly owned subsidiary of Amgen ("Merger Sub"), pursuant to which Merger Sub will be merged with and into ChemoCentryx (the "Merger") with ChemoCentryx surviving the Merger as a wholly owned subsidiary of Amgen.	Management	For	For
2.	To approve, on a non-binding, advisory basis, certain compensation that will or may be paid or become payable to ChemoCentryx's named executive officers that is based on or otherwise relates to the Merger.	Management	For	For
3.	To approve the adjournment of the Special Meeting to a later date or dates if necessary to solicit additional proxies if there are insufficient votes to adopt the Merger Agreement at the time of the Special Meeting.	Management	For	For

CHINOOK THERAPEUTICS, INC.

Security	16961L106	Meeting Type	Annual
Ticker Symbol	KDNY	Meeting Date	09-Jun-2023
Record Date	17-Apr-2023

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Michelle Griffin		For	For
	2	Eric Dobmeier		For	For
2.	Ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.		Management	For	For
3.	Advisory vote on the compensation of the Company's named executive officers.		Management	For	For
4.	Approval of the Company's Amended and Restated Certificate of Incorporation.		Management	For	For
5.	Approval of the Company's Amended and Restated 2015 Equity Incentive Plan.		Management	For	For

CODEXIS, INC.

Security	192005106	Meeting Type	Annual
Ticker Symbol	CDXS	Meeting Date	13-Jun-2023
Record Date	20-Apr-2023

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Stephen Dilly, MBBS PhD		For	For
	2	Alison Moore, Ph.D.		For	For
	3	Rahul Singhvi, Sc.D.		For	For
2.	To ratify the selection of BDO USA, LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2023.		Management	For	For
3.	To approve, by non-binding advisory vote, the compensation of our named executive officers.		Management	For	For
4.	To approve, by non-binding advisory vote, the frequency of future stockholder advisory votes to approve the compensation of the named executive officers.		Management	1 Year	For
5.	To approve an amendment to our certificate of incorporation to increase the number of authorized shares of our common stock.		Management	For	For
6.	To approve the Codexis, Inc. 2023 Employee Stock Purchase Plan.		Management	For	For
7.	To approve an amendment to the Codexis, Inc. 2019 Incentive Award Plan.		Management	For	For

CORBUS PHARMACEUTICALS HOLDINGS, INC.

Security	21833P103	Meeting Type	Special
Ticker Symbol	CRBP	Meeting Date	20-Dec-2022
Record Date	07-Nov-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Adoption and Approval of an Amendment to the Company's Charter to Effect a Reverse Stock Split of our Shares of Common Stock Issued and Outstanding or Held by the Company in the Treasury, at a Specific Ratio, Ranging From One-for-Four (1:4) to One-for- Forty (1:40), with the Exact Ratio to be Determined by the Board.	Management	For	For
2.	Approval of the Adjournment of the Special Meeting to the Extent There are Insufficient Votes at the Meeting to Approve the Reverse Stock Split Proposal.	Management	For	For
Q.	Your Series A Preferred Stock will be voted in the same manner as you have instructed your common stock on Proposal 1. If you wish to vote your Series A shares in a DIFFERENT manner, indicate YES and provide instructions on proposal 1a. Mark "for" = yes or "against" = no.	Management	No Action	None
1a.	To vote my Series A Preferred Stock differently on Proposal 1.	Management	For	For

CORBUS PHARMACEUTICALS HOLDINGS, INC.

Security	21833P301	Meeting Type	Annual
Ticker Symbol	CRBP	Meeting Date	18-May-2023
Record Date	24-Mar-2023

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Yuval Cohen		For	For
	2	Alan Holmer		For	For
	3	Avery W. Catlin		For	For
	4	Rachelle Jacques		For	For
	5	John Jenkins		For	For
	6	Peter Salzmann		For	For
	7	Anne Altmeyer		For	For
	8	Yong Ben		For	For
2.	Ratification of EisnerAmper LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023.		Management	For	For
3.	Approval, on an advisory basis, of the executive compensation of the Company's named executive officers.		Management	For	For

CRINETICS PHARMACEUTICALS INC.

Security	22663K107	Meeting Type	Annual
Ticker Symbol	CRNX	Meeting Date	16-Jun-2023
Record Date	17-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class II Director for a three-year term to expire at the 2026 Annual Meeting: Caren Deardorf	Management	For	For
1.2	Election of Class II Director for a three-year term to expire at the 2026 Annual Meeting: Weston Nichols, Ph.D.	Management	For	For
1.3	Election of Class II Director for a three-year term to expire at the 2026 Annual Meeting: Stephanie S. Okey, M.S.	Management	For	For
2.	To consider and vote upon the ratification of the appointment of BDO USA, LLP as our independent registered public accounting firm for the year ending December 31, 2023.	Management	For	For
3.	To consider and vote upon, on an advisory basis, the compensation of the Company's named executive officers.	Management	For	For
4.	To consider and vote upon, on an advisory basis, whether the stockholder vote to approve the compensation of the Company's named executive officers should occur every one, two or three years.	Management	1 Year	For

CRISPR THERAPEUTICS AG

Security	H17182108	Meeting Type	Annual
Ticker Symbol	CRSP	Meeting Date	08-Jun-2023
Record Date	17-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Approval of the Swiss management report, the consolidated financial statements and the statutory financial statements of the Company for the year ended December 31, 2022.	Management	For	For
2.	Approval of the appropriation of financial results.	Management	For	For
3.	Discharge of the members of the Board of Directors and Executive Committee.	Management	For	For
4.a	Re-election of Rodger Novak, M.D., as member and Chairman	Management	For	For
4.b	Re-election of Samarth Kulkarni, Ph.D. as a member to the Board of Directors	Management	For	For
4.c	Re-election of Ali Behbahani, M.D. as a member to the Board of Directors	Management	For	For
4.d	Re-election of Maria Fardis, Ph.D. as a member to the Board of Directors	Management	For	For
4.e	Re-election of H. Edward Fleming, Jr., M.D. as a member to the Board of Directors	Management	For	For
4.f	Re-election of Simeon J. George, M.D. as a member to the Board of Directors	Management	For	For
4.g	Re-election of John T. Greene as a member to the Board of Directors	Management	For	For
4.h	Re-election of Katherine A. High, M.D. as a member to the Board of Directors	Management	For	For
4.i	Re-election of Douglas A. Treco, Ph.D. as a member to the Board of Directors	Management	For	For
5.a	Re-election of Ali Behbahani, M.D. as a member of the Compensation Committee	Management	For	For
5.b	Election of H. Edward Fleming, Jr., M.D. as a member of the Compensation Committee	Management	For	For
5.c	Re-election of Simeon J. George, M.D. as a member of the Compensation Committee	Management	For	For
5.d	Re-election of John T. Greene as a member of the Compensation Committee	Management	For	For
6.a	Binding vote on maximum non-performance-related compensation for members of the Board of Directors from the 2023 Annual General Meeting to the 2024 annual general meeting of shareholders.	Management	For	For
6.b	Binding vote on maximum equity for members of the Board of Directors from the 2023 Annual General Meeting to the 2024 annual general meeting of shareholders.	Management	For	For
6.c	Binding vote on maximum non-performance-related compensation for members of the Executive Committee from July 1, 2023 to June 30, 2024.	Management	For	For
6.d	Binding vote on maximum variable compensation for members of the Executive Committee for the current year ending December 31, 2023.	Management	For	For
6.e	Binding vote on maximum equity for members of the Executive Committee from the 2023 Annual General Meeting to the 2024 annual general meeting of shareholders.	Management	For	For
6.f	Non-binding advisory vote on the 2022 Compensation Report.	Management	For	For
7.	Non-binding advisory vote to approve the compensation paid to the Company's named executive officers under U.S. securities law requirements.	Management	For	For
8.	Approval of a capital band.	Management	For	For
9.	Approval of an increase in the conditional share capital for employee equity plans.	Management	For	For
10.	Approval of an amendment to the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan.	Management	For	For
11.	Approval of a reduction in the maximum size of the Board of Directors.	Management	For	For
12a	Approval of amendments to the Articles of Association to reflect revised Swiss corporate law and other changes: Additions to the purpose of the Company.	Management	For	For
12b	Approval of amendments to the Articles of Association to reflect revised Swiss corporate law and other changes: General Meeting abroad and virtual General Meeting.	Management	For	For
12c	Approval of amendments to the Articles of Association to reflect revised Swiss corporate law and other changes: Inclusion of a jurisdiction clause.	Management	For	For
12d	Approval of amendments to the Articles of Association to reflect revised Swiss corporate law and other changes: Alignment with compulsory new regulations.	Management	For	For
12e	Approval of amendments to the Articles of Association to reflect revised Swiss corporate law and other changes: Editorial and other changes.	Management	For	For
13.	Re-election of the independent voting rights representative.	Management	For	For
14.	Re-election of the auditors.	Management	For	For
15.	Transact any other business that may properly come before the 2023 Annual General Meeting or any adjournment or postponement thereof.	Management	For	For

CURASEN THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	21-Oct-2022
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Amendment To Certificate Of Incorporation	Management	For	For
2.	Series A Preferred Stock Extension Financing	Management	For	For
3.	Waiver of Preemptive Rights	Management	For	For
4.	General Authority and Ratification	Management	For	For

CURASEN THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	3-Jan-2023
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Amendment to Amended and Restated 2016 Equity Incentive Plan	Management	For	For
2.	General Authority and Ratification	Management	For	For

CYTOKINETICS, INCORPORATED

Security	23282W605	Meeting Type	Annual
Ticker Symbol	CYTK	Meeting Date	10-May-2023
Record Date	21-Mar-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class I Director: Edward M. Kaye, M.D.	Management	For	For
1b.	Election of Class I Director: Wendell Wierenga, Ph.D.	Management	For	For
1c.	Election of Class I Director: Nancy J. Wysenski	Management	For	For
2.	To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to permit the exculpation of the Company's directors.	Management	For	For
3.	To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to permit the exculpation of senior officers of the Company.	Management	For	For
4.	To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.	Management	For	For
5.	To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the Proxy Statement.	Management	For	For
6.	To determine, on an advisory basis, the frequency with which the stockholders of the Company wish to have an advisory vote on the compensation of the named executive officers.	Management	1 Year	For

DENALI THERAPEUTICS INC.

Security	24823R105	Meeting Type	Annual
Ticker Symbol	DNLI	Meeting Date	01-Jun-2023
Record Date	04-Apr-2023

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Jennifer Cook		For	For
	2	David Schenkein, M.D.		For	For
	3	Ryan Watts, Ph.D.		For	For
2.	Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2023		Management	For	For
3.	Advisory vote on executive compensation		Management	For	For

DYNACURE

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	10-Oct-2022
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To approve the Term Sheet and the principle of the Merger subject to the terms and conditions set forth therein; and	Management	For	For
2.	To waive their rights to the liquidation preference under the Shareholders’ Agreement in connection with the contemplated Merger, subject to their replacement by new preference rights as described in the Term Sheet	Management	For	For

DYNACURE

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	23-Jan-2023
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Merger with Flamingo	Management	For	For

EDGEWISE THERAPEUTICS INC

Security	28036F105	Meeting Type	Annual
Ticker Symbol	EWTX	Meeting Date	09-Jun-2023
Record Date	14-Apr-2023

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Laura Brege		For	For
	2	Badreddin Edris, Ph.D.		For	For
	3	Jonathan Root, M.D.		For	For
2.	Ratify the selection of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.		Management	For	For

ELI LILLY AND COMPANY

Security	532457108	Meeting Type	Annual
Ticker Symbol	LLY	Meeting Date	01-May-2023
Record Date	21-Feb-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director to serve a three-year term: William G. Kaelin, Jr.	Management	For	For
1b.	Election of Director to serve a three-year term: David A. Ricks	Management	For	For
1c.	Election of Director to serve a three-year term: Marschall S. Runge	Management	For	For
1d.	Election of Director to serve a three-year term: Karen Walker	Management	For	For
2.	Approval, on an advisory basis, of the compensation paid to the company's named executive officers.	Management	For	For
3.	Advisory vote on frequency of future advisory votes on named executive officer compensation.	Management	1 Year	For
4.	Ratification of the appointment of Ernst & Young LLP as the independent auditor for 2023.	Management	For	For
5.	Approval of amendments to the company's Articles of Incorporation to eliminate the classified board structure.	Management	For	For
6.	Approval of amendments to the company's Articles of Incorporation to eliminate supermajority voting provisions.	Management	For	For
7.	Shareholder proposal to publish an annual report disclosing lobbying activities.	Shareholder	Against	For
8.	Shareholder proposal to eliminate supermajority voting requirements.	Shareholder	Against	For
9.	Shareholder proposal to establish and report on a process by which the impact of extended patent exclusivities on product access would be considered in deciding whether to apply for secondary and tertiary patents.	Shareholder	Against	For
10.	Shareholder proposal to report on risks of supporting abortion.	Shareholder	Against	For
11.	Shareholder proposal to disclose lobbying activities and alignment with public policy positions and statements.	Shareholder	Against	For
12.	Shareholder proposal to report on effectiveness of the company's diversity, equity, and inclusion efforts.	Shareholder	Against	For
13.	Shareholder proposal to adopt a policy to require certain third-party organizations to annually report expenditures for political activities before Lilly contributes to an organization.	Shareholder	Against	For

EXELIXIS, INC.

Security	30161Q104	Meeting Type	Contested-Annual
Ticker Symbol	EXEL	Meeting Date	31-May-2023
Record Date	03-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Company Nominee: Maria C. Freire	Management	For	For
1B.	Company Nominee: Alan M. Garber	Management	For	For
1C.	Company Nominee: Michael M. Morrissey	Management	For	For
1D.	Company Nominee: Stelios Papadopoulos	Management	For	For
1E.	Company Nominee: George Poste	Management	For	For
1F.	Company Nominee: Julie Anne Smith	Management	For	For
1G.	Company Nominee: Lance Willsey	Management	For	For
1H.	Company Nominee: Jacqueline Wright	Management	For	For
1I.	Company Nominee: Jack L. Wyszomierski	Management	For	For
1J.	Company Recommended Farallon-Caligan Nominee: Tomas J. Heyman	Management	For	For
1K.	Company Recommended Farallon-Caligan Nominee: Robert "Bob" Oliver, Jr.	Management	For	For
1L.	Farallon-Caligan Nominee: David E. Johnson	Management	Withheld	*
2.	To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Exelixis' independent registered public accounting firm for the fiscal year ending December 29, 2023.	Management	For	For
3.	To approve, on an advisory basis, the compensation of Exelixis' named executive officers, as disclosed in the Proxy Statement.	Management	For	For
4.	To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of Exelixis' named executive officers.	Management	1 Year	For

FLAMINGO THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	28-Mar-2023
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Reports	Management	For	For
2.	Creation of new classes of shares according to the report of the board of directors in accordance with Articles 7:155, 7:179, 7:180 and 7:191 of the Companies and Associations Code	Management	For	For
3.	Issue of new shares by capital increase in cash	Management	For	For
4.	Cancellation and issuance of subscription rights	Management	For	For
5.	Issue of anti-dilutive subscription rights	Management	For	For
6.	Confirmation of the cancellation of all securities or rights giving access to the capital of Dynacure SA in the context of the merger	Management	For	For
7.	Proxies	Management	For	For

FLAMINGO THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	19-May-2023
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Acknowledgment of the report of the statutory auditor	Management	For	For
2.	Approval of the annual accounts for the fiscal year ended on 31 December 2022	Management	For	For
3.	Allocation of the results	Management	For	For
4.	Release of liability to the directors and the statutory auditor for the exercise of their mandate during the past fiscal year	Management	For	For

FULCRUM THERAPEUTICS INC

Security	359616109	Meeting Type	Annual
Ticker Symbol	FULC	Meeting Date	08-Jun-2023
Record Date	10-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class I Director to serve for a 3-year term expiring at the 2026 Annual meeting: Alan Ezekowitz	Management	For	For
1.2	Election of Class I Director to serve for a 3-year term expiring at the 2026 Annual meeting: Sonja Banks	Management	For	For
2.	To approve an amendment to the Company's 2019 Stock Incentive Plan to modify the automatic increase to the share reserve provision.	Management	For	For
3.	To approve an amendment to the Company's Restated Certificate of Incorporation to limit the liability of certain Company officers as permitted by recent amendments to Delaware law.	Management	For	For
4.	To ratify the appointment of Ernst & Young as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2023.	Management	For	For

FUSION PHARMACEUTICALS INC

Security	36118A100	Meeting Type	Annual
Ticker Symbol	FUSN	Meeting Date	14-Jun-2023
Record Date	18-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director to serve until the next annual meeting: Donald Bergstrom, M.D., Ph.D.	Management	For	For
1.2	Election of Director to serve until the next annual meeting: Pablo Cagnoni, M.D.	Management	For	For
1.3	Election of Director to serve until the next annual meeting: Johan Christenson, M.D., Ph.D.	Management	For	For
1.4	Election of Director to serve until the next annual meeting: Barbara Duncan	Management	For	For
1.5	Election of Director to serve until the next annual meeting: Steve Gannon	Management	For	For
1.6	Election of Director to serve until the next annual meeting: Chau Khuong	Management	For	For
1.7	Election of Director to serve until the next annual meeting: Philina Lee, Ph.D.	Management	For	For
1.8	Election of Director to serve until the next annual meeting: Heather Preston, M.D.	Management	For	For
1.9	Election of Director to serve until the next annual meeting: John Valliant, Ph.D.	Management	For	For
2.	To appoint PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.	Management	For	For

G1 THERAPEUTICS, INC.

Security	3621LQ109	Meeting Type	Annual
Ticker Symbol	GTHX	Meeting Date	15-Jun-2023
Record Date	18-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class III Director: Garry A. Nicholson	Management	For	For
1.2	Election of Class III Director: Mark A. Velleca, M.D., Ph.D.	Management	For	For
1.3	Election of Class III Director: Glenn P. Muir	Management	For	For
2.	An advisory (non-binding) vote to approve executive compensation	Management	For	For
3.	The ratification of the appointment of PricewaterhouseCoopers LLP as G1 Therapeutics, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2023	Management	For	For

GALERA THERAPEUTICS, INC.

Security	36338D108	Meeting Type	Annual
Ticker Symbol	GRTX	Meeting Date	14-Jun-2023
Record Date	21-Apr-2023

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Michael Powell, Ph.D.		For	For
	2	Linda West		For	For
2.	To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.		Management	For	For

GILEAD SCIENCES, INC.

Security	375558103	Meeting Type	Annual
Ticker Symbol	GILD	Meeting Date	03-May-2023
Record Date	15-Mar-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Jacqueline K. Barton, Ph.D.	Management	For	For
1b.	Election of Director: Jeffrey A. Bluestone, Ph.D.	Management	For	For
1c.	Election of Director: Sandra J. Horning, M.D.	Management	For	For
1d.	Election of Director: Kelly A. Kramer	Management	For	For
1e.	Election of Director: Kevin E. Lofton	Management	For	For
1f.	Election of Director: Harish Manwani	Management	For	For
1g.	Election of Director: Daniel P. O'Day	Management	For	For
1h.	Election of Director: Javier J. Rodriguez	Management	For	For
1i.	Election of Director: Anthony Welters	Management	For	For
2.	To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.	Management	For	For
3.	To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.	Management	For	For
4.	To approve, on an advisory basis, the frequency of future advisory stockholder votes on executive compensation.	Management	1 Year	For
5.	To approve an amendment and restatement of the Gilead Sciences, Inc. Employee Stock Purchase Plan and the Gilead Sciences, Inc. International Employee Stock Purchase Plan.	Management	For	For
6.	To vote on a stockholder proposal, if properly presented at the meeting, requesting the Board implement a process to nominate at least one more candidate than the number of directors to be elected.	Shareholder	Against	For
7.	To vote on a stockholder proposal, if properly presented at the meeting, requesting the Board amend the company governing documents to give street name shares and non-street name shares an equal right to call a special stockholder meeting.	Shareholder	Against	For
8.	To vote on a stockholder proposal, if properly presented at the meeting, requesting a report on a process by which the impact of extended patent exclusivities on product access would be considered in deciding whether to apply for secondary and tertiary patents.	Shareholder	Against	For

GUARDANT HEALTH, INC.

Security	40131M109	Meeting Type	Annual
Ticker Symbol	GH	Meeting Date	14-Jun-2023
Record Date	17-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class II Director: Ian Clark	Management	For	For
1b.	Election of Class II Director: Meghan Joyce	Management	For	For
1c.	Election of Class II Director: Samir Kaul	Management	For	For
2.	Ratification of the appointment of Deloitte & Touche LLP as Guardant Health, Inc.'s independent registered public accounting firm for the year ending December 31, 2023.	Management	For	For
3.	Non-binding advisory vote to approve Guardant Health, Inc.'s named executive officer compensation.	Management	For	For

HARPOON THERAPEUTICS INC

Security	41358P106	Meeting Type	Annual
Ticker Symbol	HARP	Meeting Date	22-Jun-2023
Record Date	25-Apr-2023

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Mark Chin		For	For
	2	Andrew Robbins		For	For
2.	To approve an amendment to our amended and restated certificate of incorporation to effect a reverse stock split of our issued and outstanding common stock at a ratio of 1- for-2 to 1-for-10, to be determined in the sole discretion of the Board of Directors.		Management	For	For
3.	To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.		Management	For	For

HORIZON THERAPEUTICS PLC

Security	G46188101	Meeting Type	Special
Ticker Symbol	HZNP	Meeting Date	24-Feb-2023
Record Date	19-Jan-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Ordinary Resolution to approve the Scheme of Arrangement and authorize the directors of Horizon to take all such actions as they consider necessary or appropriate for carrying the Scheme of Arrangement into effect.	Management	For	For
2.	Special Resolution to amend the articles of association of Horizon so that any Horizon Shares that are issued on or after the Voting Record Time to persons other than Acquirer Sub or its nominee(s) will either be subject to the terms of the Scheme of Arrangement or be immediately and automatically acquired by Acquirer Sub and/or its nominee(s) for the Scheme Consideration.	Management	For	For
3.	Ordinary Resolution to approve, on a non-binding, advisory basis, specified compensatory arrangements between Horizon and its named executive officers relating to the Transaction.	Management	For	For
4.	Ordinary Resolution to approve any motion by the Chairman to adjourn the EGM or any adjournments thereof, to solicit additional proxies in favor of the approval of the resolutions if there are insufficient votes at the time of the EGM to approve resolutions 1 and 2.	Management	For	For

HORIZON THERAPEUTICS PLC

Security	G46188111	Meeting Type	Special
Ticker Symbol	HZNP	Meeting Date	24-Feb-2023
Record Date	19-Jan-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.	That the Scheme of Arrangement in its original form or with or subject to any modification(s), addition(s) or condition(s) approved or imposed by the Irish High Court be agreed to.	Management	For	For

IDEXX LABORATORIES, INC.

Security	45168D104	Meeting Type	Annual
Ticker Symbol	IDXX	Meeting Date	17-May-2023
Record Date	20-Mar-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director (Proposal One): Daniel M. Junius	Management	For	For
1b.	Election of Director (Proposal One): Lawrence D. Kingsley	Management	For	For
1c.	Election of Director (Proposal One): Sophie V. Vandebroek, PhD	Management	For	For
2.	Ratification of Appointment of Independent Registered Public Accounting Firm. To ratify the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year (Proposal Two).	Management	For	For
3.	Advisory Vote on Executive Compensation. To approve a nonbinding advisory resolution on the Company's executive compensation (Proposal Three).	Management	For	For
4.	Advisory Vote on the Frequency of Advisory Votes on Executive Compensation. To recommend, by nonbinding advisory vote, the frequency of future advisory votes on the Company's executive compensation (Proposal Four).	Management	1 Year	For

ILLUMINA, INC.

Security	452327109	Meeting Type	Contested-Annual
Ticker Symbol	ILMN	Meeting Date	25-May-2023
Record Date	03-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Illumina Nominee: Frances Arnold, Ph.D.	Management	For	For
1B.	Illumina Nominee: Francis A. deSouza	Management	Withheld	For
1C.	Illumina Nominee: Caroline D. Dorsa	Management	Withheld	For
1D.	Illumina Nominee: Robert S. Epstein, M.D.	Management	Withheld	For
1E.	Illumina Nominee: Scott Gottlieb, M.D.	Management	For	For
1F.	Illumina Nominee: Gary S. Guthart, Ph.D.	Management	Withheld	For
1G.	Illumina Nominee: Philip W. Schiller	Management	For	For
1H.	Illumina Nominee: Susan E. Siegel	Management	For	For
1I.	Illumina Nominee: John W. Thompson	Management	Withheld	For
1J.	Icahn Group Nominee OPPOSED by the Company: Vincent J. Intrieri	Management	For	For
1K.	Icahn Group Nominee OPPOSED by the Company: Jesse A. Lynn	Management	Withheld	For
1L.	Icahn Group Nominee OPPOSED by the Company: Andrew J. Teno	Management	Withheld	For
2.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.	Management	For	For
3.	To approve, on an advisory basis, the compensation provided to our named executive officers as disclosed in the Proxy Statement.	Management	Against	Against
4.	To approve, on an advisory basis, the frequency of holding an advisory vote to approve compensation provided to our "named executive officers".	Management	1 Year	For
5.	To approve certain amendments to the Illumina, Inc. 2015 Stock and Incentive Plan	Management	For	For

INTELLIA THERAPEUTICS, INC.

Security	45826J105	Meeting Type	Annual
Ticker Symbol	NTLA	Meeting Date	14-Jun-2023
Record Date	17-Apr-2023

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Muna Bhanji, R.Ph.		For	For
	2	John F. Crowley		For	For
	3	Jesse Goodman, MD, MPH		For	For
2.	Ratification of the appointment of Deloitte & Touche LLP as Intellia's independent registered public accounting firm for the fiscal year ending December 31, 2023.		Management	For	For
3.	Approve, on a non-binding advisory basis, the compensation of the named executive officers.		Management	For	For
4.	Approval of an amendment to our Second Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 120,000,000 to 240,000,000.		Management	For	For

INTERCEPT PHARMACEUTICALS, INC.

Security	45845P108	Meeting Type	Annual
Ticker Symbol	ICPT	Meeting Date	24-May-2023
Record Date	31-Mar-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director to serve until the 2024 Annual Meeting: Paolo Fundarò	Management	For	For
1b.	Election of Director to serve until the 2024 Annual Meeting: Jerome Durso	Management	For	For
1c.	Election of Director to serve until the 2024 Annual Meeting: Srinivas Akkaraju, M.D., Ph.D.	Management	For	For
1d.	Election of Director to serve until the 2024 Annual Meeting: Luca Benatti, Ph.D.	Management	For	For
1e.	Election of Director to serve until the 2024 Annual Meeting: Daniel Bradbury	Management	For	For
1f.	Election of Director to serve until the 2024 Annual Meeting: Keith Gottesdiener, M.D.	Management	For	For
1g.	Election of Director to serve until the 2024 Annual Meeting: Nancy Miller-Rich	Management	For	For
1h.	Election of Director to serve until the 2024 Annual Meeting: Mark Pruzanski, M.D.	Management	For	For
1i.	Election of Director to serve until the 2024 Annual Meeting: Dagmar Rosa-Bjorkeson	Management	For	For
1j.	Election of Director to serve until the 2024 Annual Meeting: Gino Santini	Management	For	For
1k.	Election of Director to serve until the 2024 Annual Meeting: Glenn Sblendorio	Management	For	For
2.	FOR the approval of the Company's 2023 Equity Incentive Plan.	Management	For	For
3.	FOR the approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.	Management	For	For
4.	FOR the ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023.	Management	For	For

INTRA-CELLULAR THERAPIES, INC.

Security	46116X101	Meeting Type	Annual
Ticker Symbol	ITCI	Meeting Date	23-Jun-2023
Record Date	27-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: Eduardo Rene Salas	Management	For	For
2.	To ratify of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023.	Management	For	For
3.	To approve by an advisory vote the compensation of the Company's named executive officers, as disclosed in the proxy statement.	Management	For	For

IO LIGHT HOLDINGS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	27-Sep-2022
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Approval of Subsidiary Transfer Documents	Management	For	For
2.	General Resolutions	Management	For	For

IO LIGHT HOLDINGS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	30-Dec-2022
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Approval of Series B Financing	Management	For	For
2.	Approval of Amended and Restated Certification of Incorporation	Management	For	For
3.	Approval of Amended and Restated Stockholders Agreement	Management	For	For

IONIS PHARMACEUTICALS, INC.

Security	462222100	Meeting Type	Annual
Ticker Symbol	IONS	Meeting Date	01-Jun-2023
Record Date	03-Apr-2023

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Spencer R. Berthelsen		For	For
	2	Joan E. Herman		For	For
	3	B. Lynne Parshall		For	For
	4	Joseph H. Wender		For	For
2.	To approve, by non-binding vote, executive compensation.		Management	For	For
3.	To approve, by non-binding vote, the frequency of future advisory votes on executive compensation.		Management	1 Year	For
4.	To approve an amendment of the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 5,500,000 shares to an aggregate of 35,200,000 shares.		Management	For	For
5.	To ratify increasing the vesting of future initial stock option and restricted stock unit awards to new non- employee Directors from one year to three years.		Management	For	For
6.	To ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2023 fiscal year.		Management	For	For

IQVIA HOLDINGS INC.

Security	46266C105	Meeting Type	Annual
Ticker Symbol	IQV	Meeting Date	18-Apr-2023
Record Date	17-Feb-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Carol J. Burt	Management	For	For
1b.	Election of Director: Colleen A. Goggins	Management	For	For
1c.	Election of Director: Sheila A. Stamps	Management	For	For
2.	Approve an advisory (non-binding) resolution to approve IQVIA's executive compensation (say-on-pay).	Management	For	For
3.	Approve a Company proposal to amend IQVIA's Certificate of Incorporation to adopt a stockholders' right to request a special stockholders' meeting.	Management	For	For
4.	If properly presented, a stockholder proposal concerning special stockholder meetings.	Shareholder	For	Against
5.	If properly presented, a stockholder proposal for separate Chairman and Chief Executive Officer roles.	Shareholder	For	Against
6.	Ratification of the appointment of PricewaterhouseCoopers LLP as IQVIA's independent registered public accounting firm for 2023.	Management	For	For

ITEOS THERAPEUTICS, INC.

Security	46565G104	Meeting Type	Annual
Ticker Symbol	ITOS	Meeting Date	13-Jun-2023
Record Date	18-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class III Director to serve until the 2026 Annual Meeting: Michel Detheux	Management	For	For
1.2	Election of Class III Director to serve until the 2026 Annual Meeting: David L. Hallal	Management	For	For
1.3	Election of Class III Director to serve until the 2026 Annual Meeting: Tim Van Hauwermeiren	Management	For	For
1.4	Election of Class III Director to serve until the 2026 Annual Meeting: Robert Iannone	Management	For	For
2.	To ratify the appointment of Deloitte Bedrijfsrevisoren / Réviseurs d'Entreprises BV/SRL as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.	Management	For	For

JAZZ PHARMACEUTICALS PLC

Security	G50871105	Meeting Type	Annual
Ticker Symbol	JAZZ	Meeting Date	28-Jul-2022
Record Date	01-Jun-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director to hold office until the 2025 Annual General Meeting: Jennifer E. Cook	Management	For	For
1b.	Election of Director to hold office until the 2025 Annual General Meeting: Patrick G. Enright	Management	For	For
1c.	Election of Director to hold office until the 2025 Annual General Meeting: Seamus Mulligan	Management	For	For
1d.	Election of Director to hold office until the 2025 Annual General Meeting: Norbert G. Riedel, Ph.D.	Management	For	For
2.	To ratify, on a non-binding advisory basis, the appointment of KPMG as the independent auditors of Jazz Pharmaceuticals plc for the fiscal year ending December 31, 2022 and to authorize, in a binding vote, the Board of Directors, acting through the audit committee, to determine KPMG's remuneration.	Management	For	For
3.	To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc's named executive officers as disclosed in the proxy statement.	Management	For	For
4.	To grant the Board of Directors authority under Irish law to allot and issue ordinary shares for cash without first offering those ordinary shares to existing shareholders pursuant to the statutory pre-emption right that would otherwise apply.	Management	For	For
5.	To approve any motion to adjourn the Annual General Meeting, or any adjournments thereof, to another time and place to solicit additional proxies if there are insufficient votes at the time of the Annual General Meeting to approve Proposal 4.	Management	For	For

KARUNA THERAPEUTICS, INC.

Security	48576A100	Meeting Type	Annual
Ticker Symbol	KRTX	Meeting Date	20-Jun-2023
Record Date	24-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Bill Meury	Management	For	For
1b.	Election of Director: Laurie Olson	Management	For	For
1c.	Election of Director: David Wheadon, M.D.	Management	For	For
2.	To approve, on an advisory, non-binding basis, the compensation paid to our named executive officers.	Management	For	For
3.	To ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.	Management	For	For

KURA ONCOLOGY, INC.

Security	50127T109	Meeting Type	Annual
Ticker Symbol	KURA	Meeting Date	31-May-2023
Record Date	03-Apr-2023

Item	Proposal	Proposed by	Vote		For/Against Management
1.1	Election of Class III Director for three-year term: Diane Parks	Management	For		For
1.2	Election of Class III Director for three-year term: Mary T. Szela	Management	For		For
2.	Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2023.	Management	For	��	For
3.	Approval, on an advisory basis, of the compensation of our named executive officers during the year ended December 31, 2022.	Management	For		For
4.	Approval of an amendment to our Amended and Restated 2014 Equity Incentive Plan.	Management	For		For

LANTHEUS HOLDINGS, INC.

Security	516544103	Meeting Type	Annual
Ticker Symbol	LNTH	Meeting Date	27-Apr-2023
Record Date	06-Mar-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class II Director: Ms. Minnie Baylor-Henry	Management	For	For
1.2	Election of Class II Director: Mr. Heinz Mäusli	Management	For	For
1.3	Election of Class II Director: Ms. Julie McHugh	Management	For	For
2.	The approval, on an advisory basis, of the compensation paid to our named executive officers.	Management	For	For
3.	The approval of the Lantheus Holdings, Inc. 2023 Employee Stock Purchase Plan.	Management	For	For
4.	The ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.	Management	For	For

MADRIGAL PHARMACEUTICALS INC.

Security	558868105	Meeting Type	Annual
Ticker Symbol	MDGL	Meeting Date	15-Jun-2023
Record Date	27-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Re-election of Class I Director: Paul A. Friedman, M.D.	Management	For	For
1.2	Re-election of Class I Director: Kenneth M. Bate	Management	For	For
1.3	Re-election of Class I Director: James M. Daly	Management	For	For
2.	To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.	Management	For	For
3.	Advisory vote to approve executive compensation.	Management	For	For
4.	Amendment of Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation.	Management	For	For

MARINUS PHARMACEUTICALS, INC.

Security	56854Q200	Meeting Type	Annual
Ticker Symbol	MRNS	Meeting Date	24-May-2023
Record Date	27-Mar-2023

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Tim M. Mayleben		For	For
	2	Saraswathy V Nochur PhD		For	For
	3	Christine Silverstein		For	For
2.	Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.		Management	For	For
3.	Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers as disclosed in the proxy statement.		Management	For	For

MEDPACE HOLDINGS, INC.

Security	58506Q109	Meeting Type	Annual
Ticker Symbol	MEDP	Meeting Date	19-May-2023
Record Date	23-Mar-2023

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Brian T. Carley		For	For
	2	F. H. Gwadry-Sridhar		For	For
	3	Robert O. Kraft		For	For
2.	To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.		Management	For	For
3.	To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy statement for the 2023 Annual Meeting.		Management	For	For

MEREO BIOPHARMA GROUP PLC

Security	589492107	Meeting Type	Special
Ticker Symbol	MREO	Meeting Date	18-Nov-2022
Record Date	14-Oct-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.	THAT Dr. Peter Fellner, Dr. Anders Ekblom, Dr. Deepika Pakianathan, Dr. Brian Schwartz and Mr. Michael Wyzga be removed from office as directors of the Company with immediate effect.	Management	Against	For
2.	THAT, conditional upon the passing of resolution 1 above, Dr. Annalisa Jenkins be appointed as director of the Company with immediate effect.	Management	Against	For
3.	THAT, conditional upon the passing of resolution 1 above, Dr. Daniel Shames be appointed as director of the Company with immediate effect.	Management	Against	For
4.	THAT, conditional upon the passing of resolution 1 above, Mr. Marc Yoskowitz be appointed as director of the Company with immediate effect.	Management	Against	For
5.	THAT, conditional upon the passing of resolution 1 above, Mr. Justin Roberts be appointed as director of the Company with immediate effect.	Management	Against	For
6.	THAT, conditional upon the passing of resolution 1 above, Mr. David Rosen be appointed as director of the Company with immediate effect.	Management	Against	For

MEREO BIOPHARMA GROUP PLC

Security	589492107	Meeting Type	Annual
Ticker Symbol	MREO	Meeting Date	22-May-2023
Record Date	10-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.	That the annual report and accounts for the financial year ended 31 December 2022, together with the directors' report and independent auditor's report thereon, be received and adopted.	Management	For	For
2.	That BDO LLP be re-appointed as auditors to hold office from the conclusion of the AGM until the conclusion of the next annual general meeting at which the Company's annual report and accounts are presented.	Management	For	For
3.	That the Directors be authorised to determine BDO LLP's remuneration.	Management	For	For
4.	That the directors' remuneration report (excluding the directors' remuneration policy), as set out in the Company's annual report and accounts for the financial year ended 31 December 2022, be approved.	Management	For	For
5.	That the directors' remuneration policy as set out in the Company's annual report and accounts for the financial year ended 31 December 2022, which takes effect from the end of this AGM, be approved.	Management	For	For
6.	That Dr. Annalisa Jenkins be re-appointed as a director of the Company.	Management	For	For
7.	That Justin Roberts be re-appointed as a director of the Company.	Management	For	For
8.	That Dr. Daniel Shames be re-appointed as a director of the Company.	Management	For	For
9.	That Marc Yoskowitz be re-appointed as a director of the Company.	Management	For	For
10.	That the Directors be generally and unconditionally authorised in accordance with section 551 of the Companies Act 2006 (the "Act") to exercise all the powers of the Company to allot shares in the Company or to grant rights to subscribe for, or to convert securities into, shares in the Company up to a maximum aggregate nominal amount of £2,494,456.76, such authority to expire on 30 June 2026, save that the Company may, before such expiry, make offers or agreements which would, or might, require ...(due to space limits, see proxy material for full proposal).	Management	For	For
11.	That, subject to Resolution 10 being passed, the Directors be generally empowered pursuant to section 570 and section 573 of the Act to allot equity securities for cash pursuant to the authority given by Resolution 10 and to sell equity securities held as treasury shares for cash pursuant to section 727 of the Act, in each case as if section 561(1) of the Act did not apply to any such allotment or sale, provided that this power shall be limited to the allotment or sale of equity securities up to an ...(due to space limits, see proxy material for full proposal).	Management	For	For

MERSANA THERAPEUTICS, INC.

Security	59045L106	Meeting Type	Annual
Ticker Symbol	MRSN	Meeting Date	08-Jun-2023
Record Date	10-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class III Director to serve until the 2026 Annual Meeting: Lawrence M. Alleva	Management	For	For
1b.	Election of Class III Director to serve until the 2026 Annual Meeting: David M. Mott	Management	For	For
1c.	Election of Class III Director to serve until the 2026 Annual Meeting: Anna Protopapas	Management	For	For
2.	To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.	Management	For	For
3.	To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.	Management	For	For
4.	To approve an amendment to the Company's Fifth Amended and Restated Certificate of Incorporation, as amended, to eliminate the supermajority voting requirement applicable to changes to Article IV thereof.	Management	For	For
5.	To approve an amendment to the Company's Fifth Amended and Restated Certificate of Incorporation, as amended, to reflect new Delaware law provisions regarding officer exculpation.	Management	For	For

MIRATI THERAPEUTICS, INC.

Security	60468T105	Meeting Type	Annual
Ticker Symbol	MRTX	Meeting Date	11-May-2023
Record Date	15-Mar-2023

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Charles M. Baum		For	For
	2	Bruce L.A. Carter		For	For
	3	Julie M. Cherrington		For	For
	4	Aaron I. Davis		For	For
	5	Faheem Hasnain		For	For
	6	Craig Johnson		For	For
	7	Maya Martinez-Davis		For	For
	8	David Meek		For	For
	9	Shalini Sharp		For	For
2.	To approve, on an advisory basis, the compensation paid to our named executive officers as disclosed in the Proxy Statement.		Management	For	For
3.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2023.		Management	For	For
4.	To approve the amendment to our 2013 Employee Stock Purchase Plan, to increase the aggregate number of shares of our common stock reserved for issuance under such plan by 750,000 shares.		Management	For	For

MODERNA, INC.

Security	60770K107	Meeting Type	Annual
Ticker Symbol	MRNA	Meeting Date	03-May-2023
Record Date	08-Mar-2023

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Stephen Berenson		For	For
	2	Sandra Horning, M.D.		For	For
	3	Paul Sagan		For	For
2.	To approve, on a non-binding, advisory basis, the compensation of our named executive officers.		Management	For	For
3.	To ratify the appointment of Ernst & Young LLP as our registered independent public accounting firm for the year ending December 31, 2023.		Management	For	For
4.	To vote on a shareholder proposal requesting a report on transferring intellectual property.		Shareholder	Against	For

NATERA, INC.

Security	632307104	Meeting Type	Annual
Ticker Symbol	NTRA	Meeting Date	09-Jun-2023
Record Date	10-Apr-2023

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Rowan Chapman		For	For
	2	Herm Rosenman		For	For
	3	Jonathan Sheena		For	For
2.	To ratify the appointment of Ernst & Young LLP as Natera, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2023.		Management	For	For
3.	To approve, on an advisory (non-binding) basis, the compensation of Natera, Inc.'s named executive officers as disclosed in the proxy statement.		Management	For	For

NEUROCRINE BIOSCIENCES, INC.

Security	64125C109	Meeting Type	Annual
Ticker Symbol	NBIX	Meeting Date	17-May-2023
Record Date	20-Mar-2023

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Kevin C. Gorman, Ph.D.		For	For
	2	Gary A. Lyons		For	For
	3	Johanna Mercier		For	For
2.	Advisory vote to approve the compensation paid to the Company's named executive officers.		Management	For	For
3.	Advisory vote on the frequency of advisory votes to approve the compensation paid to the Company's named executive officers.		Management	1 Year	For
4.	To approve an amendment to the Company's 2020 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 6,600,000 shares.		Management	Against	Against
5.	To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.		Management	For	For

NEXGEL, INC.

Security	65344E107	Meeting Type	Annual
Ticker Symbol	NXGL	Meeting Date	30-Aug-2022
Record Date	06-Jul-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Adam Levy		For	For
	2	Steven Glassman		For	For
	3	Yaakov Spinrad		For	For
	4	David Stefansky		For	For
	5	Nachum Stein		For	For
	6	Miranda J. Toledano		For	For
	7	Dr. J.B. Zeldis MD, PhD		For	For
2.	Proposal to approve an amendment to our Restated Certificate of Incorporation (the "Charter"), in substantially the form attached to the proxy statement as Annex A, reduce the total number of authorized shares of our common stock, par value $0.001 per share, each from 750,000,000 to 25,000,000.		Management	For	For
3.	Advisory vote on the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this notice.		Management	For	For
4.	Advisory vote on the frequency of future advisory votes on the compensation of the Company's named executive officers.		Management	1 Year	Against
5.	Ratification of the appointment of Turner, Stone & Company, L.L.P. as the Company's independent registered public accounting firm for the 2022 fiscal year.		Management	For	For

NEXGEL, INC.

Security	65344E107	Meeting Type	Annual
Ticker Symbol	NXGL	Meeting Date	06-Jun-2023
Record Date	11-Apr-2023

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Adam Levy		For	For
	2	Steven Glassman		For	For
	3	Scott R. Henry		For	For
	4	David Stefansky		For	For
	5	Nachum Stein		For	For
	6	Miranda J. Toledano		For	For
	7	Dr. J.B. Zeldis MD, PhD		For	For
2.	Proposal to approve the Third Amendment to the NexGel, Inc. 2019 Long-Term Incentive Plan to increase the total number of shares of common stock authorized for issuance under such plan by 300,000, to a total of 871,429 shares.		Management	For	For
3.	Ratification of the appointment of Turner, Stone & Company, L.L.P. as the Company's independent registered public accounting firm for the 2023 fiscal year.		Management	For	For

NKARTA, INC.

Security	65487U108	Meeting Type	Annual
Ticker Symbol	NKTX	Meeting Date	07-Jun-2023
Record Date	14-Apr-2023

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Ali Behbahani, M.D. MBA		For	For
	2	Zachary Scheiner, Ph.D.		For	For
2.	Ratification of the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the year ending December 31, 2023.		Management	For	For
3.	Approval of an amendment to the company's Certificate of Incorporation to provide for the exculpation of officers as permitted by the Delaware General Corporation Law.		Management	For	For

NOVAVAX, INC.

Security	670002401	Meeting Type	Annual
Ticker Symbol	NVAX	Meeting Date	11-Jul-2023
Record Date	18-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class I Director to serve for a three-year term expiring at the 2026 Annual Meeting: John C. Jacobs	Management	For	For
1b.	Election of Class I Director to serve for a three-year term expiring at the 2026 Annual Meeting: Gregg H. Alton, J.D.	Management	For	For
1c.	Election of Class I Director to serve for a three-year term expiring at the 2026 Annual Meeting: Richard J. Rodgers	Management	For	For
2.	The approval, on an advisory basis, of the compensation paid to our Named Executive Officers.	Management	For	For
3.	The approval, on an advisory basis, of holding future executive compensation advisory votes every three years, every two years, or every year.	Management	1 Year	For
4.	Amendment to the Second Amended and Restated Certificate of Incorporation of Novavax, Inc., as amended, to reflect Delaware law provisions allowing officer exculpation.	Management	For	For
5.	Amendment and restatement of the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended to increase the number of shares of common stock available for issuance thereunder by 6,170,000 shares.	Management	Against	Against
6.	Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.	Management	For	For

OCULIS HOLDING AG

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	8-Jul-2022
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1	Change of Designation of the Existing Series C Preferred Shares and Revision of the Articles of Association	Management	For	For
2.	Ordinary Share Capital Increase	Management	For	For
3.	Conditional Share Capital Increase	Management	For	For
4.	Election of Member to the Board of Directors	Management	For	For

PARTHENON THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	21-Feb-2023
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1	Pursuant to Section 1.2(e) of the Voting Agreement, Laurent Audoly be, and he hereby is, removed as the CEO Director and as a member of the Board, in each case with immediate effect	Management	For	For
2.	Following the removal of Dr. Audoly as the CEO Director pursuant to the foregoing, the CEO Director seat shall remain vacant in accordance with Section 1.2(e) of the Voting Agreement until a new Chief Executive Officer of the Company is duly qualified and appointed	Management	For	For
3.	The proper officers of the Company be, and each of them hereby is, authorized and directed, in the name of and on behalf of the Company, to prepare or cause to be prepared and to execute, deliver, verify, acknowledge, file or record any documents, instruments, certificates, statements, papers, or any amendments thereto, as in their sole judgment may be necessary, appropriate or advisable in order to effect the foregoing resolutions, and to take such further steps and do all such further acts or things as in their sole judgment may be necessary, appropriate or advisable to carry out the foregoing resolutions	Management	For	For
4.	The authority and power given hereunder be deemed retroactive and any and all actions previously taken by any officer or director of the Company in connection with these resolutions are hereby ratified and approved	Management	For	For

PRAXIS PRECISION MEDICINES, INC.

Security	74006W108	Meeting Type	Annual
Ticker Symbol	PRAX	Meeting Date	12-Jun-2023
Record Date	17-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class III Director to serve until the 2026 Annual Meeting of Stockholders: Gregory Norden	Management	For	For
1b.	Election of Class III Director to serve until the 2026 Annual Meeting of Stockholders: Marcio Souza	Management	For	For
1c.	Election of Class III Director to serve until the 2026 Annual Meeting of Stockholders: William Young	Management	For	For
2.	To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.	Management	For	For
3.	To approve on a non-binding, advisory basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2023 Annual Meeting pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion.	Management	For	For

PRECISION BIOSCIENCES, INC.

Security	74019P108	Meeting Type	Annual
Ticker Symbol	DTIL	Meeting Date	04-May-2023
Record Date	09-Mar-2023

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Michael Amoroso		For	For
	2	Geno Germano		For	For
2.	Ratification of the appointment of Deloitte & Touche LLP as Precision's independent registered public accounting firm for 2023.		Management	For	For

PRIOTHERA LIMITED

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	5-Dec-2022
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Notice of Appointment of Authorized Person	Management	For	For

PROMETHEUS BIOSCIENCES, INC.

Security	74349U108	Meeting Type	Special
Ticker Symbol	RXDX	Meeting Date	15-Jun-2023
Record Date	15-May-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To adopt the Agreement and Plan of Merger (as it may be amended from time to time, the "Merger Agreement"), dated as of April 15, 2023, by and among Merck & Co., Inc., a New Jersey corporation ("Merck"), Splash Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Merck ("Merger Sub"), and Prometheus Biosciences, Inc., a Delaware corporation ("Prometheus"), pursuant to which Merger Sub will be merged with and into Prometheus, with Prometheus surviving as a wholly owned subsidiary of Merck (the "Merger").	Management	For	For
2.	To approve, on a non-binding, advisory basis, certain compensation that will or may be paid or become payable to Prometheus' named executive officers that is based on or otherwise relates to the Merger.	Management	For	For
3.	To approve the adjournment of the special meeting to a later date or dates if necessary to solicit additional proxies if there are insufficient votes in person or by proxy to approve the proposal to adopt the Merger Agreement at the time of the special meeting.	Management	For	For

PYXIS ONCOLOGY, INC.

Security	747324101	Meeting Type	Annual
Ticker Symbol	PYXS	Meeting Date	13-Jun-2023
Record Date	20-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: Rachel Humphrey, M.D.	Management	For	For
1.2	Election of Director: Freda Lewis-Hall, M.D.	Management	For	For
1.3	Election of Director: Thomas Civik	Management	For	For
2.	Ratification of the Appointment of Ernst & Young LLP as our Independent Registered Public Accounting Firm for the Fiscal Year ending December 31, 2023	Management	For	For

QUELL THERAPEUTICS

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	2-Jun-2023
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Approval of the Limited Equity Incentive Plan	Management	For	For
2.	Approval of the new articles of association of the Company (the "New Articles") in substitution for, and to the entire exclusion of, the current articles of association of the Company	Management	For	For

RALLYBIO CORPORATION

Security	75120L100	Meeting Type	Annual
Ticker Symbol	RLYB	Meeting Date	17-May-2023
Record Date	20-Mar-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class II Director: Helen M. Boudreau	Management	For	For
1.2	Election of Class II Director: Lucian Iancovici	Management	For	For
1.3	Election of Class II Director: Christine A. Nash	Management	For	For
2.	Ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm.	Management	For	For

REATA PHARMACEUTICALS, INC.

Security	75615P103	Meeting Type	Annual
Ticker Symbol	RETA	Meeting Date	07-Jun-2023
Record Date	12-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class II Director to serve until the 2026 Annual Meeting: Martin W. Edwards, M.D.	Management	For	For
1.2	Election of Class II Director to serve until the 2026 Annual Meeting: R. Kent McGaughy, Jr.	Management	For	For
1.3	Election of Class II Director to serve until the 2026 Annual Meeting: Christy J. Oliger	Management	For	For
2.	An advisory (non-binding) vote on a resolution to approve the compensation of our named executive officers.	Management	For	For
3.	The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.	Management	For	For

RECODE THERAPEUTICS

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	6-Jan-2023
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Amendment No. 2 to Series B Preferred Stock Purchase Agreement	Management	For	For

REGENERON PHARMACEUTICALS, INC.

Security	75886F107	Meeting Type	Annual
Ticker Symbol	REGN	Meeting Date	09-Jun-2023
Record Date	11-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Joseph L. Goldstein, M.D.	Management	For	For
1b.	Election of Director: Christine A. Poon	Management	For	For
1c.	Election of Director: Craig B. Thompson, M.D.	Management	For	For
1d.	Election of Director: Huda Y. Zoghbi, M.D.	Management	For	For
2.	Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.	Management	For	For
3.	Proposal to approve, on an advisory basis, executive compensation.	Management	For	For
4.	Proposal to approve, on an advisory basis, the frequency of future advisory votes on executive compensation.	Management	1 Year	For
5.	Non-binding shareholder proposal, if properly presented, requesting report on a process by which access to medicine is considered in matters related to protecting intellectual property.	Shareholder	Against	For

REPARE THERAPEUTICS INC.

Security	760273102	Meeting Type	Annual
Ticker Symbol	RPTX	Meeting Date	08-Jun-2023
Record Date	10-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class III Director to hold office until our Annual Meeting of Shareholders in 2026: Samarth Kulkarni, Ph.D.	Management	For	For
1.2	Election of Class III Director to hold office until our Annual Meeting of Shareholders in 2026: Briggs Morrison, M.D.	Management	For	For
1.3	Election of Class III Director to hold office until our Annual Meeting of Shareholders in 2026: Lloyd M. Segal	Management	For	For
2.	To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in this proxy statement.	Management	For	For
3.	To appoint Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023, and to authorize the Company's board of directors to fix Ernst & Young LLP's remuneration.	Management	For	For

SAREPTA THERAPEUTICS, INC.

Security	803607100	Meeting Type	Annual
Ticker Symbol	SRPT	Meeting Date	08-Jun-2023
Record Date	14-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class II Director to hold office until the 2025 Annual Meeting: Richard J. Barry	Management	For	For
1.2	Election of Class II Director to hold office until the 2025 Annual Meeting: M. Kathleen Behrens, Ph.D.	Management	For	For
1.3	Election of Class II Director to hold office until the 2025 Annual Meeting: Stephen L. Mayo, Ph. D.	Management	For	For
1.4	Election of Class II Director to hold office until the 2025 Annual Meeting: Claude Nicaise, M.D.	Management	For	For
2.	Advisory vote to approve, on a non-binding basis, named executive officer compensation	Management	For	For
3.	Approve an amendment to the Company's 2018 Equity Incentive Plan (the "2018 Plan") to increase the maximum aggregate number of shares of common stock that may be issued pursuant to awards granted under the 2018 Plan by 2,500,000 shares to 13,187,596 shares	Management	For	For
4.	Approve an amendment to the Amended and Restated 2013 Employee Stock Purchase Plan (as amended and restated on June 27, 2016 and amended on June 6, 2019) (the "2016 ESPP") to increase the number of shares of our common stock authorized for issuance under the 2016 ESPP by 300,000 shares to 1,400,000 shares	Management	For	For
5.	Advisory vote on whether an advisory vote on executive compensation should be held every one, two or three years	Management	1 Year	For
6.	Ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the current year ending December 31, 2023	Management	For	For

SCHOLAR ROCK HOLDING CORPORATION

Security	80706P103	Meeting Type	Annual
Ticker Symbol	SRRK	Meeting Date	21-Jun-2023
Record Date	24-Apr-2023

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	David Hallal		For	For
	2	Kristina Burow		For	For
	3	Michael Gilman Ph.D		For	For
2.	To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.		Management	For	For

SEAGEN INC.

Security	81181C104	Meeting Type	Special
Ticker Symbol	SGEN	Meeting Date	30-May-2023
Record Date	17-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To consider and vote on the proposal to adopt the Agreement and Plan of Merger (as it may be amended or supplemented from time to time, the "merger agreement"), dated March 12, 2023, by and among Seagen Inc. ("Seagen"), Pfizer Inc. ("Pfizer") and Aris Merger Sub, Inc., a wholly-owned subsidiary of Pfizer ("Merger Sub"), and pursuant to which Merger Sub will be merged with and into Seagen, with Seagen surviving the merger as a wholly-owned subsidiary of Pfizer (the "merger" and such proposal the "merger agreement proposal").	Management	For	For
2.	To consider and vote on the proposal to approve, on a non-binding, advisory basis, certain compensation arrangements for Seagen's named executive officers in connection with the merger (the "compensation proposal").	Management	For	For

SEAGEN INC.

Security	81181C104	Meeting Type	Annual
Ticker Symbol	SGEN	Meeting Date	31-May-2023
Record Date	03-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class I Director: David W. Gryska	Management	For	For
1b.	Election of Class I Director: John A. Orwin	Management	For	For
1c.	Election of Class I Director: Alpna H. Seth, Ph.D.	Management	For	For
2.	Approve, on an advisory basis, the compensation of Seagen's named executive officers as disclosed in the accompanying proxy statement.	Management	For	For
3.	Indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of Seagen's named executive officers.	Management	1 Year	For
4.	Approve the amendment and restatement of the Seagen Inc. Amended and Restated 2007 Equity Incentive Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance thereunder by 5,190,000 shares.	Management	For	For
5.	Ratify the appointment of PricewaterhouseCoopers LLP as Seagen's independent registered public accounting firm for the fiscal year ending December 31, 2023.	Management	For	For

SPDR SERIES TRUST

Security	78464A870	Meeting Type	Special
Ticker Symbol	XBI	Meeting Date	20-Oct-2022
Record Date	20-Jul-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Clare S. Richer		For	For
	2	Sandra G. Sponem		For	For
	3	Kristi L. Rowsell		For	For
	4	Gunjan Chauhan		For	For
	5	Carolyn M. Clancy		For	For

SUTRO BIOPHARMA, INC.

Security	869367102	Meeting Type	Annual
Ticker Symbol	STRO	Meeting Date	08-Jun-2023
Record Date	20-Apr-2023

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	William J. Newell		For	For
	2	Connie Matsui		For	For
	3	James Panek		For	For
2.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.		Management	For	For
3.	To approve, on a non-binding, advisory basis, the compensation of our named executive officers.		Management	For	For
4.	To approve the amendment and restatement of our restated certificate of incorporation to permit the exculpation of our officers from personal liability for certain breaches of the duty of care.		Management	For	For

SYNDAX PHARMACEUTICALS, INC

Security	87164F105	Meeting Type	Annual
Ticker Symbol	SNDX	Meeting Date	17-May-2023
Record Date	22-Mar-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: Pierre Legault	Management	For	For
1.2	Election of Director: Michael A. Metzger	Management	For	For
2.	To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the 2023 proxy statement.	Management	For	For
3.	To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023.	Management	For	For
4.	To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 shares to 200,000,000 shares.	Management	For	For

TACTILE SYSTEMS TECHNOLOGY, INC.

Security	87357P100	Meeting Type	Annual
Ticker Symbol	TCMD	Meeting Date	08-May-2023
Record Date	13-Mar-2023

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Valerie Asbury		For	For
	2	Bill Burke		For	For
	3	Sheri Dodd		For	For
	4	Raymond Huggenberger		For	For
	5	Daniel Reuvers		For	For
	6	Brent Shafer		For	For
	7	Carmen Volkart		For	For
2.	Ratify the appointment of Grant Thornton LLP as our independent registered public accounting firm for the year ending December 31, 2023.		Management	For	For
3.	Approve, on an advisory basis, the 2022 compensation of our named executive officers.		Management	For	For

THESEUS PHARMACEUTICALS, INC.

Security	88369M101	Meeting Type	Annual
Ticker Symbol	THRX	Meeting Date	09-Jun-2023
Record Date	13-Apr-2023

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Carl Gordon		For	For
	2	Michael Rome		For	For
2.	To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.		Management	For	For
3.	To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted by recent amendments to the Delaware General Corporation Law.		Management	For	For

TRAVERE THERAPEUTICS INC.

Security	89422G107	Meeting Type	Annual
Ticker Symbol	TVTX	Meeting Date	17-May-2023
Record Date	21-Mar-2023

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Roy Baynes		For	For
	2	Suzanne Bruhn		For	For
	3	Timothy Coughlin		For	For
	4	Eric Dube		For	For
	5	Gary Lyons		For	For
	6	Jeffrey Meckler		For	For
	7	John Orwin		For	For
	8	Sandra Poole		For	For
	9	Ron Squarer		For	For
	10	Ruth Williams-Brinkley		For	For
2.	To approve the Company's 2018 Equity Incentive Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by 2,700,000 shares.		Management	For	For
3.	To approve, on an advisory basis, the compensation of the Company's named executive officers.		Management	For	For
4.	To ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023.		Management	For	For

TSCAN THERAPEUTICS, INC.

Security	89854M101	Meeting Type	Annual
Ticker Symbol	TCRX	Meeting Date	13-Jun-2023
Record Date	17-Apr-2023

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Katina Dorton, JD, MBA		For	For
2.	To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023		Management	For	For
3.	To approve an amendment to the TScan Therapeutics, Inc. 2021 Equity Incentive Plan to increase the number of shares of voting common stock authorized for issuance under the plan by 7,500,000 shares		Management	For	For

ULTRAGENYX PHARMACEUTICAL INC.

Security	90400D108	Meeting Type	Annual
Ticker Symbol	RARE	Meeting Date	07-Jun-2023
Record Date	17-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Emil D. Kakkis, M.D., Ph.D.	Management	For	For
1b.	Election of Director: Shehnaaz Suliman, M.D.	Management	For	For
1c.	Election of Director: Daniel G. Welch	Management	For	For
2.	Approval of the 2023 Incentive Plan.	Management	For	For
3.	Approval of the Amended & Restated Employee Stock Purchase Plan.	Management	For	For
4.	Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.	Management	For	For
5.	Advisory (non-binding) vote to approve the compensation of our named executive officers.	Management	For	For

UNIQURE N.V.

Security	N90064101	Meeting Type	Annual
Ticker Symbol	QURE	Meeting Date	13-Jun-2023
Record Date	17-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Resolution to adopt the 2022 Dutch statutory annual accounts and treatment of the results.	Management	For	For
2.	Resolution to discharge liability of the members of the Board.	Management	For	For
3.	Reappointment of Madhavan Balachandran as non- executive director.	Management	For	For
4.	Reappointment of Jack Kaye as non-executive director.	Management	For	For
5.	Reappointment of Leonard Post as non-executive director.	Management	For	For
6.	Reappointment of Jeremy Springhorn as non-executive director.	Management	For	For
7.	Resolution to renew the designation of the Board as the competent body to issue Ordinary Shares and options.	Management	For	For
8.	Resolution to reauthorize the Board to exclude or limit preemptive rights upon the issuance of Ordinary Shares.	Management	For	For
9.	Resolution to reauthorize the Board to repurchase Ordinary Shares.	Management	For	For
10.	Resolution to appoint KPMG as external auditors of the Company for the financial year 2023.	Management	For	For
11.	Resolution to approve, on an advisory basis, the compensation of the named executive officers of the Company.	Management	For	For
12.	Resolution to approve the amendment and restatement of the Company's 2014 Share Incentive Plan.	Management	For	For

UNIQURE N.V.

Security	N90064101	Meeting Type	Annual
Ticker Symbol	QURE	Meeting Date	13-Jun-2023
Record Date	16-May-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Resolution to adopt the 2022 Dutch statutory annual accounts and treatment of the results.	Management	For	For
2.	Resolution to discharge liability of the members of the Board.	Management	For	For
3.	Reappointment of Madhavan Balachandran as non- executive director.	Management	For	For
4.	Reappointment of Jack Kaye as non-executive director.	Management	For	For
5.	Reappointment of Leonard Post as non-executive director.	Management	For	For
6.	Reappointment of Jeremy Springhorn as non-executive director.	Management	For	For
7.	Resolution to renew the designation of the Board as the competent body to issue Ordinary Shares and options.	Management	For	For
8.	Resolution to reauthorize the Board to exclude or limit preemptive rights upon the issuance of Ordinary Shares.	Management	For	For
9.	Resolution to reauthorize the Board to repurchase Ordinary Shares.	Management	For	For
10.	Resolution to appoint KPMG as external auditors of the Company for the financial year 2023.	Management	For	For
11.	Resolution to approve, on an advisory basis, the compensation of the named executive officers of the Company.	Management	For	For
12.	Resolution to approve the amendment and restatement of the Company's 2014 Share Incentive Plan.	Management	For	For

UNITED THERAPEUTICS CORPORATION

Security	91307C102	Meeting Type	Annual
Ticker Symbol	UTHR	Meeting Date	26-Jun-2023
Record Date	27-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Christopher Causey	Management	For	For
1b.	Election of Director: Raymond Dwek	Management	For	For
1c.	Election of Director: Richard Giltner	Management	For	For
1d.	Election of Director: Katherine Klein	Management	For	For
1e.	Election of Director: Ray Kurzweil	Management	For	For
1f.	Election of Director: Linda Maxwell	Management	For	For
1g.	Election of Director: Nilda Mesa	Management	For	For
1h.	Election of Director: Judy Olian	Management	For	For
1i.	Election of Director: Christopher Patusky	Management	For	For
1j.	Election of Director: Martine Rothblatt	Management	For	For
1k.	Election of Director: Louis Sullivan	Management	For	For
1l.	Election of Director: Tommy Thompson	Management	For	For
2.	Advisory resolution to approve executive compensation.	Management	For	For
3.	Advisory vote on the frequency of future advisory votes on executive compensation.	Management	1 Year	For
4.	Approval of the amendment and restatement of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan.	Management	For	For
5.	Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2023.	Management	For	For

VAXCYTE, INC.

Security	92243G108	Meeting Type	Annual
Ticker Symbol	PCVX	Meeting Date	13-Jun-2023
Record Date	17-Apr-2023

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Halley Gilbert, J.D.		For	For
	2	Michael E Kamarck Ph.D.		For	For
	3	Grant E Pickering M.B.A		For	For
2.	Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.		Management	For	For
3.	Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.		Management	For	For

VECTIVBIO HOLDING AG

Security	H9060V101	Meeting Type	Special
Ticker Symbol	VECT	Meeting Date	09-Dec-2022
Record Date	31-Oct-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Wouter Joustra - The Board of Directors proposes to elect Wouter Joustra as a new member of the Board of Directors for a term of office until completion of the 2023 Annual General Meeting of the Company.	Management	For	For

VECTIVBIO HOLDING AG

Security	H9060V101	Meeting Type	Annual
Ticker Symbol	VECT	Meeting Date	01-Jun-2023
Record Date	02-May-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Approval of the 2022 Statutory Financial Statements and Consolidated Financial Statements - The Board of Directors proposes that the Statutory Financial Statements and the Consolidated Financial Statements for the financial year 2022 be approved.	Management	For	For
1.2	Advisory Vote on the 2022 Compensation Report - The Board of Directors proposes that the 2022 Compensation Report be endorsed in a non-binding advisory vote.	Management	For	For
2	Appropriation of 2022 Financial Results - The Board of Directors proposes that the loss of the Company be carried forward as follows: Loss carried forward from the financial year 2021 CHF -28,435,076 Loss for the financial year 2022 CHF -36,211,404 Loss to be carried forward CHF -64,646,480.	Management	For	For
3	Discharge of the Board of Directors and of the Executive Committee - The Board of Directors proposes that all members of the Board of Directors and of the Executive Committee be discharged from liability for their activities during the financial year 2022.	Management	For	For
4.1	Re-election of Thomas Woiwode (as Chairman and member of the Board of Directors) - The Board of Directors proposes to re-elect Thomas Woiwode as Chairman and member of the Board of Directors for a term of office until completion of the 2024 Annual General Meeting.	Management	For	For
4.2	Re-election of Sandip Kapadia - The Board of Directors proposes to re-elect Sandip Kapadia as member of the Board of Directors for a term of office until completion of the 2024 Annual General Meeting.	Management	For	For
4.3	Re-election of Paul Rutherford Carter - The Board of Directors proposes to re-elect Paul Rutherford Carter as member of the Board of Directors for a term of office until completion of the 2024 Annual General Meeting.	Management	For	For
4.4	Re-election of Luca Santarelli - The Board of Directors proposes to re-elect Luca Santarelli as member of the Board of Directors for a term of office until completion of the 2024 Annual General Meeting.	Management	For	For
4.5	Re-election of Hans Schikan - The Board of Directors proposes to re-elect Hans Schikan as member of the Board of Directors for a term of office until completion of the 2024 Annual General Meeting.	Management	For	For
4.6	Re-election of Murray Willis Stewart - The Board of Directors proposes to re-elect Murray Willis Stewart as member of the Board of Directors for a term of office until completion of the 2024 Annual General Meeting.	Management	For	For
4.7	Re-election of Wouter Joustra - The Board of Directors proposes to re-elect Wouter Joustra as member of the Board of Directors for a term of office until completion of the 2024 Annual General Meeting.	Management	For	For
5.1	Re-election of Paul Rutherford Carter - The Board of Directors proposes to re-elect Paul Rutherford Carter as member of the Compensation Committee for a term of office until completion of the 2024 Annual General Meeting.	Management	For	For
5.2	Re-election of Murray Willis Stewart - The Board of Directors proposes to re-elect Murray Willis Stewart as member of the Compensation Committee for a term of office until completion of the 2024 Annual General Meeting.	Management	For	For
5.3	Re-election of Thomas Woiwode - The Board of Directors proposes to re-elect Thomas Woiwode as member of the Compensation Committee for a term of office until completion of the 2024 Annual General Meeting.	Management	For	For
6	Re-election of the Statutory Auditors - The Board of Directors proposes that Ernst & Young AG, in Basel, Switzerland, be re-elected as the Company's statutory auditors for the financial year 2023.	Management	For	For
7	Re-election of the Independent Proxy - The Board of Directors proposes that Buis Bürgi AG, Zurich, Switzerland, be re-elected as independent proxy for a term of office until completion of the 2024 Annual General Meeting.	Management	For	For
8.1	Approval of the Maximum Aggregate Amount of Compensation of the Board of Directors - The Board of Directors proposes that a maximum aggregate amount of compensation of the Board of Directors for the period from the 2023 Annual General Meeting to the 2024 Annual General Meeting of CHF 2,200,000 be approved.	Management	For	For
8.2	Approval of the Maximum Aggregate Amount of Compensation of the Executive Committee - The Board of Directors proposes that a maximum aggregate amount of compensation of the Executive Committee for the financial year 2024 of CHF 18,500,000 be approved.	Management	For	For
9	Introduction of a Capital Range - The Board of Directors proposes to cancel the existing authorized share capital pursuant to article 3a of the Articles of Association and to replace it with a capital range ranging from CHF 3,369,589.50 (lower limit) to CHF 5,054,384.25 (upper limit) as set forth in the invitation to the 2023 Annual General Meeting.	Management	For	For
10	Increase of the Conditional Share Capital for Participation Programs - The Board of Directors proposes (i) that the Company's conditional share capital for participation programs be increased by CHF 692,576.75 to the maximum amount of CHF 1,233,908.75, allowing the issuance of up to 24,678,175 registered shares with a par value of CHF 0.05 each, and, accordingly, to amend article 3b (Conditional Share Capital for Participation Programs), paragraph 1, of the Articles ...(due to space limits, see proxy material for full proposal).	Management	Against	Against
11a	Amendments to the Articles of Association - Share Certificates and Intermediated Securities, Share Register, Restrictions on Registration, Nominees - The Board of Directors proposes to amend articles 4 and 5 of the Articles of Association as set forth in the invitation to the 2023 Annual General Meeting.	Management	For	For
11b	Amendments to the Articles of Association - Shareholder Rights, General Meeting of Shareholders, Notices and Communications - The Board of Directors proposes to amend articles 7, 8, 9, 10, 13, 24 and 34 of the Articles of Association as set forth in the invitation to the 2023 Annual General Meeting.	Management	For	For
11c	Amendments to the Articles of Association - Board of Directors, Compensation of the Executive Committee, Mandates Outside the Company - The Board of Directors proposes to amend articles 18, 19, 26, 27 and 29 of the Articles of Association as set forth in the invitation to the 2023 Annual General Meeting.	Management	For	For
11d	Amendments to the Articles of Association - Jurisdiction Clause - The Board of Directors proposes to introduce a new article 35 to our Articles of Association as set forth in the invitation to the 2023 Annual General Meeting.	Management	For	For

VECTIVBIO HOLDING AG

Security	H9060V101	Meeting Type	Special
Ticker Symbol	VECT	Meeting Date	26-Jun-2023
Record Date	22-May-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Removal of the Restrictions on Registration and Exercise of Voting Rights (Conditional Resolution) - The Board of Directors proposes to amend article 5 paras. 2, 4, 5 and 6 and article 12 paras. 1 and 2 of the Articles of Association as set forth in the invitation to the Extraordinary General Meeting, provided that these amendments shall be subject to, and only become effective upon, the Completion of the Tender Offer (as defined in the invitation to the Extraordinary General Meeting).	Management	For	For
2.1	Election of Andrew Davis (as Chairperson and member of the Board of Directors) - The Board of Directors proposes to elect Andrew Davis as Chairperson and member of the Board of Directors for a term of office until completion of the 2024 Annual General Meeting, provided that this election shall be subject to, and only become effective upon, the Completion of the Tender Offer (as defined in the invitation to the Extraordinary General Meeting).	Management	For	For
2.2	Election of John Minardo (as member of the Board of Directors) - The Board of Directors proposes to elect John Minardo as member of the Board of Directors for a term of office until completion of the 2024 Annual General Meeting, provided that this election shall be subject to, and only become effective upon, the Completion of the Tender Offer (as defined in the invitation to the Extraordinary General Meeting).	Management	For	For
2.3	Election of Sravan Emany (as member of the Board of Directors) - The Board of Directors proposes to elect Sravan Emany as member of the Board of Directors for a term of office until completion of the 2024 Annual General Meeting, provided that this election shall be subject to, and only become effective upon, the Completion of the Tender Offer (as defined in the invitation to the Extraordinary General Meeting).	Management	For	For
3.1	Election of Andrew Davis - The Board of Directors proposes to elect Andrew Davis as member of the Compensation Committee for a term of office until completion of the 2024 Annual General Meeting, provided that this election shall be subject to, and only become effective upon, the Completion of the Tender Offer (as defined in the invitation to the Extraordinary General Meeting).	Management	For	For
3.2	Election of John Minardo - The Board of Directors proposes to elect John Minardo as member of the Compensation Committee for a term of office until completion of the 2024 Annual General Meeting, provided that this election shall be subject to, and only become effective upon, the Completion of the Tender Offer (as defined in the invitation to the Extraordinary General Meeting).	Management	For	For
3.3	Election of Sravan Emany - The Board of Directors proposes to elect Sravan Emany as member of the Compensation Committee for a term of office until completion of the 2024 Annual General Meeting, provided that this election shall be subject to, and only become effective upon, the Completion of the Tender Offer (as defined in the invitation to the Extraordinary General Meeting).	Management	For	For
4.	Delisting of the Company's Shares (Conditional Resolution) - The Board of Directors proposes to approve the delisting of the ordinary shares of the Company from Nasdaq, subject to (i) Completion of the Tender Offer (as defined in the invitation to the Extraordinary General Meeting) and (ii) satisfaction of the requirements under the listing rules of the Nasdaq Stock Market, LLC.	Management	For	For

VERTEX PHARMACEUTICALS INCORPORATED

Security	92532F100	Meeting Type	Annual
Ticker Symbol	VRTX	Meeting Date	17-May-2023
Record Date	23-Mar-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: Sangeeta Bhatia	Management	For	For
1.2	Election of Director: Lloyd Carney	Management	For	For
1.3	Election of Director: Alan Garber	Management	For	For
1.4	Election of Director: Terrence Kearney	Management	For	For
1.5	Election of Director: Reshma Kewalramani	Management	For	For
1.6	Election of Director: Jeffrey Leiden	Management	For	For
1.7	Election of Director: Diana McKenzie	Management	For	For
1.8	Election of Director: Bruce Sachs	Management	For	For
1.9	Election of Director: Suketu Upadhyay	Management	For	For
2.	Ratification of Ernst & Young LLP as independent Registered Public Accounting firm for the year ending December 31, 2023.	Management	For	For
3.	Advisory vote to approve named executive office compensation.	Management	For	For
4.	Advisory vote on the frequency of future advisory votes on executive compensation.	Management	1 Year	For

VYNE THERAPEUTICS INC.

Security	92941V209	Meeting Type	Annual
Ticker Symbol	VYNE	Meeting Date	10-Aug-2022
Record Date	14-Jun-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Steven Basta		For	For
	2	Anthony Bruno		For	For
	3	Elisabeth Sandoval		For	For
2.	To ratify the selection by the Audit Committee of the Company's Board of Directors of Baker Tilly US, LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022.		Management	For	For
3.	To approve and adopt an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company's common stock at a ratio ranging from 1- for-5 shares up to a ratio of 1-for-15 shares, which ratio will be selected by the Company's Board of Directors and set forth in a public announcement.		Management	For	For
4.	To approve the adjournment of the Annual Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt Proposal 3.		Management	For	For

VYNE THERAPEUTICS INC.

Security	92941V209	Meeting Type	Special
Ticker Symbol	VYNE	Meeting Date	12-Jan-2023
Record Date	16-Nov-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To approve and adopt an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company's common stock at a ratio ranging from 1- for-10 shares up to a ratio of 1-for-25 shares, which ratio will be selected by the Company's Board of Directors and set forth in a public announcement.	Management	For	For
2.	To approve the adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt Proposal 1.	Management	For	For

XENON PHARMACEUTICALS INC

Security	98420N105	Meeting Type	Annual
Ticker Symbol	XENE	Meeting Date	01-Jun-2023
Record Date	04-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: Simon Pimstone	Management	For	For
1.2	Election of Director: Dawn Svoronos	Management	For	For
1.3	Election of Director: Mohammad Azab	Management	For	For
1.4	Election of Director: Steven Gannon	Management	For	For
1.5	Election of Director: Elizabeth Garofalo	Management	For	For
1.6	Election of Director: Patrick Machado	Management	For	For
1.7	Election of Director: Ian Mortimer	Management	For	For
1.8	Election of Director: Gary Patou	Management	For	For
2.	Approve, on an advisory basis, the compensation of the Corporation's named executive officers	Management	For	For
3.	Appoint KPMG LLP as the Corporation's auditor to hold office until the next annual meeting of the Corporation or until their successors are duly elected	Management	For	For
4.	Authorizing the Audit Committee of the board of directors of the Corporation to fix the remuneration to be paid to the auditor of the Corporation	Management	For	For

ZAI LAB LTD

Security	98887Q104	Meeting Type	Annual
Ticker Symbol	ZLAB	Meeting Date	20-Jun-2023
Record Date	20-Apr-2023

Item	Proposal	Proposed by	Vote	For/Against Management
1.	THAT, Samantha (Ying) Du is hereby re-elected to serve as a director until the 2024 annual general meeting	Management	For	For
2.	THAT, Kai-Xian Chen is hereby re-elected to serve as a director until the 2024 annual general meeting	Management	For	For
3.	THAT, John D. Diekman is hereby re-elected to serve as a director until the 2024 annual general meeting	Management	For	For
4.	THAT, Richard Gaynor is hereby re-elected to serve as a director until the 2024 annual general meeting	Management	For	For
5.	THAT, Nisa Leung is hereby re-elected to serve as a director until the 2024 annual general meeting	Management	For	For
6.	THAT, William Lis is hereby re-elected to serve as a director until the 2024 annual general meeting	Management	For	For
7.	THAT, Scott Morrison is hereby re-elected to serve as a director until the 2024 annual general meeting	Management	For	For
8.	THAT, Leon O. Moulder, Jr. is hereby re-elected to serve as a director until the 2024 annual general meeting	Management	For	For
9.	THAT, Michel Vounatsos is hereby elected to serve as a director until the 2024 annual general meeting	Management	For	For
10.	THAT, Peter Wirth is hereby re-elected to serve as a director until the 2024 annual general meeting	Management	For	For
11.	THAT, the appointment of KPMG LLP and KPMG as the Company's independent registered public accounting firms and auditors to audit the Company's consolidated financial statements to be filed with the U.S. Securities and Exchange Commission and The Stock Exchange of Hong Kong Limited for the year ending December 31, 2023, respectively, is hereby approved.	Management	For	For
12.	THAT, the authority of the Board of Directors to fix the auditor compensation for 2023, is hereby approved.	Management	For	For
13.	THAT, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in this proxy statement, is hereby approved.	Management	For	For
14.	THAT, within the parameters of Rule 13.36 of the HK Listing Rules, the granting of a general mandate to the Board of Directors to allot and issue ordinary shares and/or American Depositary Shares of up to 20% of the total number of issued ordinary shares of the Company as of the date of passing of such ordinary resolution up to the next annual general meeting of shareholders of the Company, is hereby approved.	Management	For	For
15.	THAT, if Ordinary Resolution 14 is not approved, within the parameters of Rule 13.36 of the HK Listing Rules, the granting of a general mandate to the Board of Directors to allot and issue ordinary shares and/or American Depositary Shares of up to 10% of the total number of issued ordinary shares of the Company as of the date of passing of such ordinary resolution up to the next annual general meeting of shareholders of the Company, is hereby approved.	Management	For	For

SIGNATURES

Pursuant to the requirements of the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

(Registrant)		Tekla Life Sciences Investors
By (Signature and Title)*
			/s/ Daniel R. Omstead
			(Daniel R. Omstead, President)
Date	8/4/23

*Print the name and title of each signing officer under his or her signature.